New salts

ABSTRACT

There is provided pharmaceutically-acceptable acid addition salts of compounds of formula I,  
                 
wherein 
     R 1  represents C 1-2  alkyl substituted by one or more fluoro substituents;    R 2  represents C 1-2  alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

This application is a national stage filing under 35 U.S.C. 371 ofInternational Application No. PCT/SE03/00859, filed May 27, 2003, whichclaims priority from Sweeden Application No. 0201661-6, filed May 312002, the specification of which is incorporated by reference herein.International Application No. PCT/SE03/00859 was published under PCTArticle 21(2) in English.

FIELD OF THE INVENTION

This invention relates to new salts of compounds that inhibit thrombinfollowing administration to mammalian patients, to pharmaceuticalcompositions containing such salts, and to processes for obtaining them.

BACKGROUND TO THE INVENTION AND PRIOR ART

In the formulation of drug compositions, it is important for the drugsubstance to be in a form in which it can be conveniently handled andprocessed. This is of importance, not only from the point of view ofobtaining a commercially-viable manufacturing process, but also from thepoint of view of subsequent manufacture of pharmaceutical formulationscomprising the active compound.

Further, in the manufacture of drug compositions, it is important that areliable, reproducible and constant plasma concentration profile of drugis provided following administration to a patient.

Chemical stability, solid state stability, and “shelf life” of theactive ingredients are also very important factors. The drug substance,and compositions containing it, should preferably be capable of beingeffectively stored over appreciable periods of time, without exhibitinga significant change in the active component's physico-chemicalcharacteristics (e.g. its chemical composition, density, hygroscopicityand solubility).

Moreover, it is also important to be able to provide drug in a formwhich is as chemically pure as possible.

The skilled person will appreciate that, typically, if a drug can bereadily obtained in a stable form, such as a stable crystalline form,advantages may be provided, in terms of ease of handling, ease ofpreparation of suitable pharmaceutical formulations, and a more reliablesolubility profile.

International Patent Application No. PCT/SE01/02657 (WO 02/44145,earliest priority date 01 Dec. 2000, filed 30 Nov. 2001, published 06Jun. 2002) discloses a number of compounds that are, or are metabolisedto compounds which are, competitive inhibitors of trypsin-likeproteases, such as thrombin. The following three compounds are amongstthose that are specifically disclosed:

(a) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe):

which compound is referred to hereinafter as Compound A;

(b) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe):

which compound is referred to hereinafter as Compound B; and

(c) Ph(3-Cl)(5-OCH₂CH₂F)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe):

which compound is referred to hereinafter as Compound C.

Abbreviations are listed at the end of this specification.

The methoxyamidine Compounds A, B and C are metabolised following oraland/or parenteral administration to the corresponding free amidinecompounds, which latter compounds have been found to be potentinhibitors of thrombin.

Processes for the synthesis of Compounds A, B and C are described inExamples 12, 40 and 22 (respectively) of International PatentApplication No. PCT/SE01/02657.

Specific pharmaceutically-acceptable salts of Compounds A, B and C arenot disclosed in PCT/SE01/02657. Further, no information is provided inrelation to how crystalline forms of Compounds A, B or C, andparticularly salts thereof, may be prepared.

DISCLOSURE OF THE INVENTION

According to a first aspect of the invention, there is provided apharmaceutically-acceptable acid addition salt of a compound of formulaI,

wherein

-   R¹ represents C₁₋₂ alkyl substituted by one or more fluoro    substituents;-   R² represents C₁₋₂ alkyl; and-   n represents 0, 1 or 2;    which salts are referred to hereinafter as “the compounds of the    invention”.

The compounds of the invention may be in the form of a solvate, ahydrate, a mixed solvate/hydrate or, preferably, an ansolvate, such asan anhydrate. Solvates may be of one or more organic solvents, such aslower (e.g. C₁₋₄) alkyl alcohols (e.g. methanol, ethanol oriso-propanol), ketones (such as acetone), esters (such as ethyl acetate)or mixtures thereof. Additionally, tautomers of the compounds of theinvention are also included.

Preferred acid addition salts include inorganic acid addition salts,such as those of sulphuric acid, nitric acid, phosphoric acid andhydrohalic acids, such as hydrobromic acid and hydrochloric acid. Morepreferred acid addition salts include those of organic acids, such asthose of dimethylphosphoric acid; saccharinic acid; cyclohexylsulfamicacid; those of carboxylic acids (such as maleic acid, fumaric acid,aspartic acid, succinic acid, malonic acid, acetic acid, benzoic acid,terephthalic acid, hippuric acid, 1-hydroxy-2-naphthoic acid, pamoicacid, hydroxybenzoic acid and the like); those of hydroxy acids (such assalicylic acid, tartaric acid, citric acid, malic acid (includingL-(−)-malic acid and, D,L-malic acid), gluconic acid (includingD-gluconic acid), glycolic acid, ascorbic acid, lactic acid and thelike); those of amino acids (such as glutamic acid (includingD-glutamic, L-glutamic, and D,L-glutamic, acids), arginine (includingL-arginine), lysine (including L-lysine and L-lysine hydrochloride),glycine and the like); and, particularly, those of sulfonic acids, (suchas 1,2-ethanedisulfonic acid, camphorsulfonic acids (including1S-(+)-10-camphorsulfonic acid and (+/−)-camphorsulfonic acids),ethanesulfonic acid, a propanesulfonic acid (including n-propanesulfonicacid), a butanesulfonic acid, a pentanesulfonic acid, a toluenesulfonicacid, methanesulfonic acid, p-xylenesulfonic acid, 2-mesitylenesulfonicacid, naphthalenesulfonic acids (including 1,5-naphthalenesulfonic acidand 1-naphthalenesulfonic acid), benzenesulfonic acid,hydroxybenzenesulfonic acids, 2-hydroxyethanesulfonic acid,3-hydroxyethanesulfonic acid and the like).

Particularly preferred salts include those of C₁₋₆ (e.g. C₁₋₄)alkanesulfonic acids, such as ethanesulfonic acid and propanesulfonicacid (e.g. n-propanesulfonic acid) and optionally substituted (e.g. withone or more C₁₋₂ alkyl groups) arylsulfonic acids, such asbenzenesulfonic acid.

Further particularly preferred salts include those of C₁₋₆ (e.g. C₁₋₄)alkanesulfonic acids, such as ethanesulfonic acid and propanesulfonicacid (e.g. n-propanesulfonic acid), optionally substituted (e.g. withone or more C₁₋₂ alkyl groups) arylsulfonic acids, such asbenzenesulfonic acid, and optionally substituted (e.g. with one or moreC₁₋₂ alkyl groups) aryldisulfonic acids, such as1,5-naphthalenedisulfonic acid (and hemi-1,5-naphthalenedisulfonicacid).

Preferred compounds of formula I include those in which:

-   R¹ represents —OCHF₂ or —OCH₂CH₂F;-   R² represents methyl;-   n represents 0 or 2.

More preferred compounds of formula I include those in which nrepresents 0, or those in which n represents 2, so providing two fluoroatoms located at the 2- and 6-positions (i.e. the two ortho-positionsrelative to the point of attachment of the benzene ring to the —NH—CH₂—group).

Particularly preferred compounds of formula I include Compound B,Compound C and, especially, Compound A.

Compounds of the invention may be made by way of techniques, which maycomprise addition of an appropriate amount of the relevant acid to acompound of formula I in free base form, for example as describedhereinafter; conversion of one salt to another (in the case where thereis difference in the pKa values of the relevant acids and thesolubilities of the respective salts); and ion pair chromatography.

According to a further aspect of the invention, there is provided aprocess for the preparation of a compound of the invention, whichcomprises addition of an acid to a compound of formula I.

Suitable stoichiometric ratios of acid to free base are in the range0.25:1.5 to 3.0:1, such as 0.45:1.25 to 1.25:1, including 0.50:1 to 1:1.

Compounds of formula I may be prepared by the following processes(relevant information is also incorporated herein from InternationalPatent Application No. PCT/SE01/02657 (WO 02/44145, earliest prioritydate 01 Dec. 2000, filed 30 Nov. 2001, published 06 Jun. 2002)):

(i) the coupling of a compound of formula II,

wherein R¹ is as hereinbefore defined with a compound of formula III,

wherein n and R² are as hereinbefore defined, for example in thepresence of a coupling agent (e.g. oxalyl chloride in DMF, EDC, DCC,HBTU, HATU, PyBOP or TBTU), an appropriate base (e.g. pyridine, DMAP,TEA, 2,4,6-collidine or DIPEA) and a suitable organic solvent (e.g.dichloromethane, acetonitrile, EtOAc or DMF);

(ii) the coupling of a compound of formula IV,

wherein R¹ is as hereinbefore defined with a compound of formula V,

wherein n and R² are as hereinbefore defined, for example underconditions as described in process (i) above; or

(iii) reaction of a protected derivative of a compound corresponding toa compound of formula I, except that, in place of the group OR², a Hatom is present (i.e. a corresponding free amidine compound), whichprotected derivative is, for example, a compound of formula VI,

wherein R^(a) represents, for example, —CH₂CH₂—Si(CH₃)₃ or benzyl, andR¹ and n are as hereinbefore defined, or a tautomer thereof, with acompound of formula VII,R²ONH₂   VIIwherein R² is as hereinbefore defined, or an acid addition salt thereof,for example at between room and reflux temperature in the presence of anappropriate organic solvent (e.g. THF, CH₃CN, DMF or DMSO), followed byremoval of the —C(O)OR^(a) group under conditions known to those skilledin the art (e.g. by reacting with QF or TFA (e.g. as describedhereinafter)).

Compounds of formula II are available using known and/or standardtechniques.

For example, compounds of formula II may be prepared by reaction of analdehyde of formula VIII,

wherein R¹ is as hereinbefore defined with:

(a) a compound of formula IX,R″CN   IXwherein R″ represents H or (CH₃)₃Si, for example at room, or elevated,temperature (e.g. below 100° C.) in the presence of a suitable organicsolvent (e.g. chloroform or methylene chloride) and, if necessary, inthe presence of a suitable base (e.g. TEA) and/or a suitable catalystsystem (e.g. benzylammonium chloride or zinc iodide, or using a chiralcatalyst, for example as described in Chem. Rev., (1999) 99, 3649),followed by hydrolysis under conditions that are well known to thoseskilled in the art (e.g. as described hereinafter);

(b) NaCN or KCN, for example in the presence of NaHSO₃ and water,followed by hydrolysis;

(c) chloroform, for example at elevated temperature (e.g. above roomtemperature but below 100° C.) in the presence of a suitable organicsolvent (e.g. chloroform) and, if necessary, in the presence of asuitable catalyst system (e.g. benzylammonium chloride), followed byhydrolysis;

(d) a compound of formula X,

wherein M represents Mg or Li, followed by oxidative cleavage (e.g.ozonolysis or osmium or ruthenium catalysed) under conditions which arewell known to those skilled in the art; or

(e) tris(methylthio)methane under conditions which are well known tothose skilled in the art, followed by hydrolysis in the presence of e.g.HgO and HBF₄.

Compounds of formula II may alternatively be prepared by oxidation of acompound of formula XI,

or a derivative thereof that is optionally protected at the secondaryhydroxyl group, wherein R¹ is as hereinbefore defined, in the presenceof a suitable oxidising agent (e.g. a combination of a suitable freeradical oxidant (such as TEMPO) and an appropriate hypochlorite salt(such as sodium hypochlorite)) under conditions known to those skilledin the art, for example at between −10° C. and room temperature, in thepresence of a suitable solvent (e.g. water, acetone or a mixturethereof), an appropriate salt (e.g. an alkali metal halide such aspotassium bromide) and a suitable base (e.g. an alkali metal carbonateor hydrogen carbonate such as sodium hydrogen carbonate).

In the formation of compounds of formula II, the skilled person willappreciate that the required enantiomeric form may be prepared by way ofroutine enantiomeric separation techniques, for example by anenantiospecific derivatisation step. This may be achieved, for exampleby an enzymatic process. Such enzymatic processes include, for example,transesterification of the α-OH group at between room and refluxtemperature (e.g. at between 45 and 65° C.) in the presence of asuitable enzyme (e.g. Lipase PS Amano), an appropriate ester (e.g. vinylacetate) and a suitable solvent (e.g. methyl tert-butyl ether). Thederivatised isomer may then be separated from the unreacted isomer byconventional separation techniques (e.g. chromatography).

Groups added to compounds of formula II in such a derivatisation stepmay be removed either before any further reactions or at any later stagein the synthesis of compounds of formula I. The additional groups may beremoved using conventional techniques (e.g. for esters of the α-OHgroup, hydrolysis under conditions known to those skilled in the art(e.g. at between room and reflux temperature in the presence of asuitable base (e.g. NaOH) and an appropriate solvent (e.g. MeOH, wateror mixtures thereof))).

Compounds of formula III may be prepared by coupling(S)-azetidine-2-carboxylic acid to a compound of formula V, ashereinbefore defined, for example under similar conditions to thosedescribed herein for preparation of compounds of formula I.

Compounds of formula IV may be prepared by coupling a compound offormula II as hereinbefore defined to (S)-azetidine-2-carboxylic acid,for example under similar conditions to those described herein forpreparation of compounds of formula I.

Compounds of formula VI may be prepared by reaction of a correspondingcompound of formula II, as hereinbefore defined, with a compound offormula XII,

wherein n and R^(a) are as hereinbefore defined, for example undersimilar conditions to those described hereinbefore for synthesis ofcompounds of formula I.

Alternatively, compounds of formula VI may be prepared by reaction of acompound corresponding to a compound of formula I, except that, in placeof the group —OR², a H atom is present (i.e. a corresponding freeamidine compound), with a compound of formula XIII,L¹COOR^(a)   XIIIwherein L¹ represents a suitable leaving group, such as halo ornitrophenyl (e.g. 4-nitrophenyl), and R^(a) is as hereinbefore defined,for example at or around room temperature in the presence of suitablebase (e.g. NaOH, for example in aqueous solution) and an appropriateorganic solvent (e.g. methylene chloride).

Compounds of formula VIII are available using known and/or standardtechniques. For example, they may be prepared by:

(i) metallation (wherein the metal may be, for example, an alkali metalsuch as Li or, preferably, a divalent metal such as Mg) of a compound offormula XIV,

wherein Hal represents a halogen atom selected from Cl, Br and I and R¹is as hereinbefore defined, followed by reaction with a suitable sourceof the formyl group (such as N,N-dimethylformamide), for example underconditions described hereinafter;

(ii) reduction of a compound of formula XV,

wherein R¹ is as hereinbefore defined in the presence of a suitablereducing agent (e.g. DIBAL-H); or

(iii) oxidation of a compound of formula XVI,

wherein R¹ is as hereinbefore defined in the presence of a suitableoxidising agent (e.g. MnO₂, pyridinium chlorochromate, a combination ofDMSO and oxalyl chloride, or SO₃ pyridine complex in DMSO).

Compounds of formula XII may be prepared by reaction of(S)-azetidine-2-carboxylic acid with a compound of formula XVII,

wherein n and R^(a) are as hereinbefore defined, for example undersimilar conditions to those described hereinbefore for synthesis ofcompounds of formula I.

Compounds of formula V, VII, IX, X, XI, XIII, XIV, XV, XVI, XVII and(S)-azetidine-2-carboxylic acid are either commercially available, areknown in the literature, or may be obtained either by analogy with theprocesses described herein, or by conventional synthetic procedures, inaccordance with standard techniques, from readily available startingmaterials using appropriate reagents and reaction conditions. Freeamidine equivalents of compounds of formula I may be prepared inanalogous fashion to processes described herein for preparation ofcompounds of formula I.

We have found that certain compounds of the invention have the advantagethat they may be prepared in crystalline form.

According to a further aspect of the invention there is provided acompound of the invention in substantially crystalline form.

Although we have found that it is possible to produce compounds of theinvention in forms which are greater than 80% crystalline, by“substantially crystalline” we include greater than 20%, preferablygreater than 30%, and more preferably greater than 40% (e.g. greaterthan any of 50, 60, 70, 80 or 90%) crystalline.

According to a further aspect of the invention there is also provided acompound of the invention in partially crystalline form. By “partiallycrystalline” we include 5% or between 5% and 20% crystalline.

The degree (%) of crystallinity may be determined by the skilled personusing X-ray powder diffraction (XRPD). Other techniques, such as solidstate NMR, FT-IR, Raman spectroscopy, differential scanning calorimetry(DSC) and microcalorimetry, may also be used.

Compounds of the invention, and particularly crystalline compounds ofthe invention, may have improved stability when compared to compoundsdisclosed in PCT/SE01/02657.

The term “stability” as defined herein includes chemical stability andsolid state stability.

By “chemical stability”, we include that it may be possible to storecompounds of the invention in an isolated form, or in the form of aformulation in which it is provided in admixture with pharmaceuticallyacceptable carriers, diluents or adjuvants (e.g. in an oral dosage form,such as a tablet, capsule etc.), under normal storage conditions, withan insignificant degree of chemical degradation or decomposition.

By “solid state stability”, we include that it may be possible to storecompounds of the invention in an isolated solid form, or in the form ofa solid formulation in which it is provided in admixture withpharmaceutically acceptable carriers, diluents or adjuvants (e.g. in anoral dosage form, such as a tablet, capsule etc.), under normal storageconditions, with an insignificant degree of solid state transformation(e.g. crystallisation, recrystallisation, solid state phase transition,hydration, dehydration, solvatisation or desolvatisation).

Examples of “normal storage conditions” include temperatures of betweenminus 80 and plus 50° C. (preferably between 0 and 40° C. and morepreferably room temperatures, such as 15 to 30° C.), pressures ofbetween 0.1 and 2 bars (preferably at atmospheric pressure), relativehumidities of between 5 and 95% (preferably 10 to 60%), and/or exposureto 460 lux of UV/visible light, for prolonged periods (i.e. greater thanor equal to six months). Under such conditions, compounds of theinvention may be found to be less than 15%, more preferably less than10%, and especially less than 5%, chemically degraded/decomposed, orsolid state transformed, as appropriate. The skilled person willappreciate that the above-mentioned upper and lower limits fortemperature, pressure and relative humidity represent extremes of normalstorage conditions, and that certain combinations of these extremes willnot be experienced during normal storage (e.g. a temperature of 50° C.and a pressure of 0.1 bar).

Preferred compounds of the invention that may be prepared in crystallineform include salts of C₁₋₆ (e.g. C₂₋₆, such as C₂₋₄) alkanesulfonicacids, such as ethanesulfonic acid, propanesulfonic acid (e.g.n-propanesufonic acid) and optionally substituted arylsulfonic acids,such as benzenesulfonic acid.

It may be possible to crystallise salts of Compounds A, B and C with orwithout the presence of a solvent system (e.g. crystallisation may befrom a melt, under supercritical conditions, or achieved bysublimation). However, we prefer that crystallisation occurs from anappropriate solvent system.

Appropriate solvent systems that may be used in a crystallisationprocess may be heterogeneous or homogeneous and may thus comprise one ormore organic solvents, such as lower alkyl acetates (e.g. linear orbranched C₁₋₆ alkyl acetates, such as ethyl acetate, iso-propyl acetateand butyl acetate); lower (e.g. linear or branched C₁₋₆) alkyl alcohols,such as hexan-1-ol, 3-methylbutan-1-ol, pentan-1-ol, pentan-2-ol,4-methyl-2-pentanol and 2-methyl-1-propanol, methanol, ethanol,n-propanol, iso-propanol and butanol (e.g. n-butanol); aliphatichydrocarbons (e.g. linear or branched C₅₋₈ alkanes, such as n-pentane,n-heptane and iso-octane); aromatic hydrocarbons (e.g. benzene, toluene,o-xylene, m-xylene and p-xylene); chlorinated alkanes (e.g. chloroformand dichloromethane); dialkyl (e.g. di-C₁₋₆ alkyl) ketones (e.g.acetone, methyl iso-butyl ketone), acetonitrile, dimethylformamide,dialkyl ethers (e.g. diethyl ether, di-iso-propyl ether, di-n-propylether, di-n-butyl ether and tert-butyl methyl ether); and/or aqueoussolvents, such as water. Mixtures of any of the above-mentioned solventsmay be used.

Different salts may have different solubilities in any given solvent atany given temperature. In this respect, compounds of the invention maybe readily soluble in certain solvents (including some of thosementioned above), yet may be less soluble in others. Solvents in whichcompounds are the invention are poorly soluble may be termed“antisolvents”.

Suitable solvents in which compounds of the invention may be readilysoluble include lower alkyl alcohols (such as methanol, ethanol andiso-propanol). Lower alkyl acetates (such as ethyl acetate andiso-propyl acetate), lower dialkyl ketones (such as methyl iso-butylketone), aliphatic hydrocarbons (such as iso-octane and n-heptane) andaromatic hydrocarbons (such as toluene) may be employed as antisolvents.

Crystallisation of compounds of the invention from an appropriatesolvent system may be achieved by attaining supersaturation in a solventsystem comprising compound of the invention (e.g. by cooling, by solventevaporation and/or via the addition of antisolvent).

It is preferred that crystalline compounds of the invention (andparticularly crystalline Compounds A, B and C) are provided by one ormore of the following methods:

(i) preparation of a compound of the invention in amorphous form,followed by dissolution of that salt in an appropriate solvent system,such as a polar solvent (e.g. a lower alkyl alcohol, a lower alkylacetate, a lower dialkyl ketone, or a mixture of these solvents), andsubsequent crystallisation (optionally initiated by seeding).Crystallisation may be effected in this way by dissolving compound ofthe invention in a solvent in which it is readily soluble (e.g. a loweralkyl alcohol), followed by addition of antisolvent (e.g. a lower alkylacetate or a lower di alkyl ketone), or by dissolving compound in amixture of a solvent in which it is readily soluble and an antisolvent,and subsequent crystallisation; or

(ii) reaction crystallisation (or precipitation), which comprises addingan appropriate amount of acid to a compound of formula I, and theneither:

-   (a) direct crystallisation, for example from a solvent system that    comprises an antisolvent (e.g. a lower alkyl acetate, a lower    dialkyl ketone or a hydrocarbon); or-   (b) subsequent addition of an appropriate antisolvent to facilitate    crystallisation (e.g. formation of compound of the invention in a    solvent in which it is readily soluble (e.g. a lower alkyl alcohol),    followed by addition of antisolvent (e.g. an acetate, a lower alkyl    ketone or a hydrocarbon)),    in both of which processes (a) and (b), acid and/or base may be    initially provided in association with the appropriate solvent    system, and in both of which processes (a) and (b), crystallisation    may be initiated by seeding.

In the case of process (i) above, preferred solvents may include methyliso-butyl ketone, iso-propanol, ethyl acetate, iso-propyl acetate andmixtures thereof.

In the case of process (ii) above, depending on the salt that is to beformed:

(a) preferred solvents for “direct” crystallisation may includeiso-propanol, iso-propyl acetate, n-butyl acetate, toluene or,preferably, methyl iso-butyl ketone or ethyl acetate; and

(b) when the crystallisation employs antisolvent, preferred solvents inwhich compounds of the invention are readily soluble may includemethanol, ethanol or, preferably, iso-propanol; and preferredantisolvents may include methyl iso-butyl ketone, n-butyl acetate,toluene, iso-octane, n-heptane or, preferably, ethyl acetate oriso-propyl acetate.

In any of processes (i) or (ii), the skilled person will appreciatethat, following salt formation, at least part of the solvent(s) may beremoved, and then the resultant mixture re-dissolved prior to performinga crystallisation as described herein.

When the crystalline compound of the invention to be formed is anethanesulfonate salt of Compound A, and:

(1) the process performed is process (i), amorphous salt may be slurriedin either methyl iso-butyl ketone or a mixture of iso-propanol and ethylacetate; and

(2) the process performed is process (ii), a direct crystallisation maybe achieved by adding ethanesulfonic acid, optionally in the form of asolution in methyl iso-butyl ketone, to a solution of Compound A inmethyl iso-butyl ketone. Alternatively, ethanesulfonic acid may be addedto a solution of Compound A in iso-propanol, and ethyl acetate may thenbe added as antisolvent.

When the crystalline compound of the invention to be formed is ann-propanesulfonate salt of Compound A, and:

(I) the process performed is process (i), amorphous salt may be slurriedin a mixture of iso-propanol and iso-propyl acetate, or in a mixture ofiso-propanol and ethyl acetate; and

(II) the process performed is process (ii), n-propanesulfonic acid maybe added to a solution of Compound A in iso-propanol and then ethylacetate, or iso-propyl acetate, added as antisolvent.

When the crystalline compound of the invention to be formed is abenzenesulfonate salt of Compound A, and:

(A) the process performed is process (i), amorphous salt may be slurriedin ethyl acetate, methyl iso-butyl ketone or iso-propyl acetate; and

(B) the process performed is process (ii), benzenesulfonic acid may beadded to a solution of Compound A in ethyl acetate, and then a smallamount of iso-propanol added to facilitate transformation intocrystalline material. Alternatively, benzenesulfonic acid may be addedto a solution of Compound A in iso-propanol, and then ethyl acetateadded as antisolvent.

According to a further aspect of the invention, there is provided aprocess for the preparation of a crystalline compound of the inventionwhich comprises crystallising a compound of the invention from anappropriate solvent system.

Crystallisation temperatures and crystallisation times depend upon thesalt that is to be crystallised, the concentration of that salt insolution, and the solvent system which is used.

Crystallisation may also be initiated and/or effected by way of standardtechniques, for example with or without seeding with crystals of theappropriate crystalline compound of the invention.

Compounds of the invention that are anhydrates contain no more than 3%,preferably 2%, more preferably 1% and more preferably 0.5% (w/w) water,whether such water is bound (crystal water or otherwise) or not.

Different crystalline forms of the compounds of the invention may bereadily characterised using X-ray powder diffraction (XRPD) methods, forexample as described hereinafter.

In order to ensure that a particular crystalline form is prepared in theabsence of other crystalline forms, crystallisations are preferablycarried out by seeding with nuclei and/or seed crystals of the desiredcrystalline form in substantially complete absence of nuclei and/or seedcrystals of other crystalline forms. Seed crystals of appropriatecompound may be prepared, for example, by way of slow evaporation ofsolvent from a portion of solution of appropriate salt.

Compounds of the invention may be isolated using techniques which arewell known to those skilled in the art, for example decanting, filteringor centrifuging.

Compounds may be dried using standard techniques.

Further purification of compounds of the invention may be effected usingtechniques, which are well known to those skilled in the art. Forexample impurities may be removed by way of recrystallisation from anappropriate solvent system. Suitable temperatures and times for therecrystallisation depend upon the concentration of the salt in solution,and upon the solvent system which is used.

When compounds of the invention are crystallised, or recrystallised, asdescribed herein, the resultant salt may be in a form which has improvedchemical and/or solid state stability, as mentioned hereinbefore.

Pharmaceutical Preparations and Medical Uses

Compounds of the invention may be administered parenterally or orally tomammalian patients (including humans), and may thereafter be metabolisedin the body to form compounds that are pharmacologically active (i.e.they act as “prodrugs” of active compounds).

Thus, the compounds of the invention are useful because they aremetabolised in the body following oral or parenteral administration toform compounds which possess pharmacological activity. The compounds ofthe invention are therefore indicated as pharmaceuticals.

According to a further aspect of the invention there is thus providedthe compounds of the invention for use as pharmaceuticals.

In particular, compounds of the invention are metabolised followingadministration to form potent inhibitors of thrombin, for example as maybe demonstrated in the tests described in inter alia internationalpatent application No. PCT/SE01/02657, as well as international patentapplications WO 02/14270, WO 01/87879 and WO 00/42059, the relevantdisclosures in which documents are hereby incorporated by reference.

By “prodrug of a thrombin inhibitor”, we include compounds that form athrombin inhibitor, in an experimentally-detectable amount, and within apredetermined time (e.g. about 1 hour), following oral or parenteraladministration.

The compounds of the invention are thus expected to be useful in thoseconditions where inhibition of thrombin is required, and/or conditionswhere anticoagulant therapy is indicated, including the following:

The treatment and/or prophylaxis of thrombosis and hypercoagulability inblood and/or tissues of animals including man. It is known thathypercoagulability may lead to thrombo-embolic diseases. Conditionsassociated with hypercoagulability and thrombo-embolic diseases whichmay be mentioned include inherited or acquired activated protein Cresistance, such as the factor V-mutation (factor V Leiden), andinherited or acquired deficiencies in antithrombin III, protein C,protein S, heparin cofactor II. Other conditions known to be associatedwith hypercoagulability and thrombo-embolic disease include circulatingantiphospholipid antibodies (Lupus anticoagulant), homocysteinemi,heparin induced thrombocytopenia and defects in fibrinolysis, as well ascoagulation syndromes (e.g. disseminated intravascular coagulation(DIC)) and vascular injury in general (e.g. due to surgery).

The treatment of conditions where there is an undesirable excess ofthrombin without signs of hypercoagulability, for example inneurodegenerative diseases such as Alzheimer's disease.

Particular disease states which may be mentioned include the therapeuticand/or prophylactic treatment of venous thrombosis (e.g. DVT) andpulmonary embolism, arterial thrombosis (e.g. in myocardial infarction,unstable angina, thrombosis-based stroke and peripheral arterialthrombosis), and systemic embolism usually from the atrium during atrialfibrillation (e.g. non-valvular atrial fibrillation) or from the leftventricle after transmural myocardial infarction, or caused bycongestive heart failure; prophylaxis of re-occlusion (i.e. thrombosis)after thrombolysis, percutaneous trans-luminal angioplasty (PTA) andcoronary bypass operations; the prevention of re-thrombosis aftermicrosurgery and vascular surgery in general.

Further indications include the therapeutic and/or prophylactictreatment of disseminated intravascular coagulation caused by bacteria,multiple trauma, intoxication or any other mechanism; anticoagulanttreatment when blood is in contact with foreign surfaces in the bodysuch as vascular grafts, vascular stents, vascular catheters, mechanicaland biological prosthetic valves or any other medical device; andanticoagulant treatment when blood is in contact with medical devicesoutside the body such as during cardiovascular surgery using aheart-lung machine or in haemodialysis; the therapeutic and/orprophylactic treatment of idiopathic and adult respiratory distresssyndrome, pulmonary fibrosis following treatment with radiation orchemotherapy, septic shock, septicemia, inflammatory responses, whichinclude, but are not limited to, edema, acute or chronic atherosclerosissuch as coronary arterial disease and the formation of atheroscleroticplaques, cerebral arterial disease, cerebral infarction, cerebralthrombosis, cerebral embolism, peripheral arterial disease, ischaemia,angina (including unstable angina), reperfusion damage, restenosis afterpercutaneous trans-luminal angioplasty (PTA) and coronary artery bypasssurgery.

Compounds of the invention that inhibit trypsin and/or thrombin may alsobe useful in the treatment of pancreatitis.

The compounds of the invention are thus indicated both in thetherapeutic and/or prophylactic treatment of these conditions.

According to a further aspect of the present invention, there isprovided a method of treatment of a condition where inhibition ofthrombin is required which method comprises administration of atherapeutically effective amount of a compound of the invention to aperson suffering from, or susceptible to, such a condition.

The compounds of the invention will normally be administered orally,intravenously, subcutaneously, buccally, rectally, dermally, nasally,tracheally, bronchially, by any other parenteral route or viainhalation, in the form of pharmaceutical preparations comprisingcompound of the invention in a pharmaceutically acceptable dosage form.

Depending upon the disorder and patient to be treated and the route ofadministration, the compositions may be administered at varying doses.

The compounds of the invention may also be combined and/orco-administered with any antithrombotic agent(s) with a differentmechanism of action, such as one or more of the following: theantiplatelet agents acetylsalicylic acid, ticlopidine and clopidogrel;thromboxane receptor and/or synthetase inhibitors; fibrinogen receptorantagonists; prostacyclin mimetics; phosphodiesterase inhibitors;ADP-receptor (P₂T) antagonists; and inhibitors of carboxypeptidase U(CPU).

The compounds of the invention may further be combined and/orco-administered with thrombolytics such as one or more of tissueplasminogen activator (natural, recombinant or modified), streptokinase,urokinase, prourokinase, anisoylated plasminogen-streptokinase activatorcomplex (APSAC), animal salivary gland plasminogen activators, and thelike, in the treatment of thrombotic diseases, in particular myocardialinfarction.

According to a further aspect of the invention there is provided apharmaceutical formulation including a compound of the invention, inadmixture with a pharmaceutically acceptable adjuvant, diluent orcarrier.

Suitable daily doses of the compounds of the invention in therapeutictreatment of humans are about 0.001-100 mg/kg body weight at peroraladministration and 0.001-50 mg/kg body weight at parenteraladministration, excluding the weight of any acid counter-ion.

For the avoidance of doubt, as used herein, the term “treatment”includes therapeutic and/or prophylactic treatment.

Compounds of the invention have the advantage that they may be moreefficacious, be less toxic, be longer acting, have a broader range ofactivity, be more potent, produce fewer side effects, be more easilyabsorbed, and/or have a better pharmacokinetic profile (e.g. higher oralbioavailability and/or lower clearance), than, and/or have other usefulpharmacological, physical, or chemical, properties over, compounds knownin the prior art. Compounds of the invention may have the furtheradvantage that they may be administered less frequently than compoundsknown in the prior art.

Compounds of the invention may also have the advantage that they are ina form which provides for improved ease of handling. Further, compoundsof the invention have the advantage that they may be produced in formswhich may have improved chemical and/or solid state stability (includinge.g. due to lower hygroscopicity). Thus, such compounds of the inventionmay be stable when stored over prolonged periods.

Compounds of the invention may also have the advantage that they may becrystallised in good yields, in a high purity, rapidly, conveniently,and at a low cost.

The invention is illustrated, but in no way limited, by the followingexamples, with reference to the enclosed figures in which:

FIG. 1 shows an X-ray powder diffractogram for crystalline Compound A,ethanesulfonic acid salt.

FIG. 2 shows an X-ray powder diffractogram for crystalline Compound A,benzenesulfonic acid salt.

FIG. 3 shows an X-ray powder diffractogram for crystalline Compound A,n-propanesulfonic acid salt.

FIG. 4 shows an X-ray powder diffractogram for crystalline Compound A,n-butanesulfonic acid salt.

FIG. 5 shows an X-ray powder diffractogram for crystalline Compound B,hemi-1,5-naphthalenedisulfonic acid salt.

GENERAL PROCEDURES

TLC was performed on silica gel. Chiral HPLC analysis was performedusing a 46 mm×250 mm Chiralcel OD column with a 5 cm guard column. Thecolumn temperature was maintained at 35° C. A flow rate of 1.0 mL/minwas used. A Gilson 115 UV detector at 228 nm was used. The mobile phaseconsisted of hexanes, ethanol and trifluroacetic acid and theappropriate ratios are listed for each compound. Typically, the productwas dissolved in a minimal amount of ethanol and this was diluted withthe mobile phase.

In Preparations A to C below, LC-MS/MS was performed using a HP-1100instrument equipped with a CTC-PAL injector and a 5 Tm, 4×100 mmThermoQuest, Hypersil BDS-C18 column. An API-3000 (Sciex) MS detectorwas used. The flow rate was 1.2 mL/min and the mobile phase (gradient)consisted of 10-90% acetonitrile with 90-10% of 4 mM aq. ammoniumacetate, both containing 0.2% formic acid. Otherwise, low resolutionmass spectra (LRMS) were recorded using a Micromass ZQ spectrometer inESI posneg switching ion mode (mass range m/z 100-800); and highresolution mass spectra (HRMS) were recorded using a Micromass LCTspectrometer in ES negative ionization mode (mass range m/z 100-1000)with Leucine Enkephalin (C₂₈H₃₇N₅O₇) as internal mass standard.

¹H NMR spectra were recorded using tetramethylsilane as the internalstandard. ¹³C NMR spectra were recorded using the listed deuteratedsolvents as the internal standard.

Otherwise, MeOD was used as solvent and the MeOD signal as internalstandard (¹H Λ=3.30 ppm; ¹³C Λ=49 ppm).

X-ray powder diffraction analysis (XRPD) was performed using variableslits on samples prepared according to standard methods with and withoutusing any internal standard, for example those described in Giacovazzo,C. et al (1995), Fundamentals of Crystallography, Oxford UniversityPress; Jenkins, R. and Snyder, R. L. (1996), Introduction to X-RayPowder Diffractometry, John Wiley & Sons, New York; Bunn, C. W. (1948),Chemical Crystallography, Clarendon Press, London; or Klug, H. P. &Alexander, L. E. (1974), X-ray Diffraction Procedures, John Wiley andSons, New York. X-ray analyses were performed using a Siemens D5000diffractometer and a Philips X'Pert MPD.

Differential scanning calorimetry (DSC) was performed using a MettlerDSC820 instrument, according to standard methods, for example thosedescribed in Höhne, G. W. H. et al (1996), Differential ScanningCalorimetry, Springer, Berlin.

Thermogravimetric analysis (TGA) was performed using a Mettler ToledoTGA850 instrument.

It will be appreciated by the skilled person that crystalline forms ofcompounds of the invention may be prepared by analogy with processesdescribed herein and/or in accordance with the Examples below, and mayshow essentially the same XRPD diffraction patterns and/or DSC and/orTGA thermograms as those disclosed herein. By “essentially the same”XRPD diffraction patterns and/or DSC and/or TGA thermograms, we includethose instances when it is clear from the relevant patterns and/orthermograms (allowing for experimental error) that essentially the samecrystalline form has been formed. When provided, DSC onset temperaturesmay vary in the range ±5° C. (e.g. ±2° C.), and XRPD distance values mayvary in the range ±2 on the last decimal place. It will be appreciatedby the skilled person that XRPD intensities may vary when measured foressentially the same crystalline form for a variety of reasonsincluding, for example, preferred orientation.

The intensity of XRPD data is generally within a margin of error ofapproximately plus or minus 20 to 40%. The relative intensities may becharacterised according to the following definitions: % RelativeIntensity Definition 60-100  vs (very strong) 21-59.9 s (strong)  7-20.9m (medium) 4-6.9 w (weak) <1-3.9   vw (very weak)

In the Examples section, unless stated otherwise, when seeding isperformed the seeds are obtained from the first Example in whichcrystalline material of that salt is obtained. For example, in Example13, seeds are obtained from Example 11.

Preparation A: Preparation of Compound A

(i) 3-Chloro-5-methoxybenzaldehyde

3,5-Dichloroanisole (74.0 g, 419 mmol) in THF (200 mL) was addeddropwise to magnesium metal (14.2 g, 585 mmol, pre-washed with 0.5 NHCl) in THF (100 mL) at 25° C. After the addition, 1,2-dibromoethane(3.9 g, 20.8 mmol) was added dropwise. The resultant dark brown mixturewas heated at reflux for 3 h. The mixture was cooled to 0° C., andN,N-dimethylformamide (60 mL) was added in one portion. The mixture waspartitioned with diethyl ether (3×400 mL) and 6N HCl (500 mL). Thecombined organic extracts were washed with brine (300 mL), dried(Na₂SO₄), filtered and concentrated in vacuo to give an oil. Flashchromatography (2×) on silica gel eluting with Hex:EtOAc (4:1) affordedthe sub-title compound (38.9 g, 54%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 9.90 (s, 1H), 7.53 (s, 1H), 7.38 (s, 1H), 7.15(s, 1H), 3.87 (s, 3H).

(ii) 3-Chloro-5-hydroxybenzaldehyde

A solution of 3-chloro-5-methoxybenzaldehyde (22.8 g, 134 mmol; see step(i) above) in CH₂Cl₂ (250 mL) was cooled to 0° C. Boron tribromide (15.8mL, 167 mmol) was added dropwise over 15 min. After stirring, thereaction-mixture for 2 h, H₂O (50 mL) was added slowly. The solution wasthen extracted with Et₂O (2×100 mL). The organic layers were combined,dried (Na₂SO₄), filtered and concentrated in vacuo. Flash chromatographyon silica gel eluting with Hex:EtOAc (4:1) afforded the sub-titlecompound (5.2 g, 25%).

¹H NMR (300 MHz, CDCl₃) δ 9.85 (s, 1H), 7.35 (s,1H), 7.20 (s,1H), 7.10(s,1H), 3.68 (s,1H)

(iii) 3-Chloro-5-difluoromethoxybenzaldehyde

A solution of 3-chloro-5-hydroxybenzaldehyde (7.5g, 48 mmol; see step(ii) above) in 2-propanol (250 mL) and 30% KOH (100 mL) was heated toreflux. While stirring, CHClF₂ was bubbled into the reaction mixture for2 h. The reaction mixture was cooled, acidified with 1N HCl andextracted with EtOAc (2×100 mL). The organics were washed with brine(100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. Flashchromatography on silica gel eluting with Hex:EtOAc (4:1) afforded thesub-title compound (4.6 g, 46%).

¹H NMR (300 MHz, CDCl₃) δ 9.95 (s, 1H), 7.72 (s, 1H), 7.52 (s, 1H), 7.40(s, 1H), 6.60 (t, J_(H-F)=71.1 Hz, 1H)

(iv) Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OTMS)CN

A solution of 3-chloro-5-difluoromethoxybenzaldehyde (4.6 g, 22.3 mmol;see step (iii) above) in CH₂Cl₂ (200 mL) was cooled to 0° C. ZnI₂ (1.8g, 5.6 mmol) and trimethylsilyl cyanide (2.8 g, 27.9 mmol) were addedand the reaction mixture was allowed to warm to room temperature andstirred for 15 h. The mixture was partially concentrated in vacuoyielding the sub-title compound as a liquid, which was used directly instep (v) below without further purification or characterization.

(v) Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(NH)OEt

Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OTMS)CN (6.82 g, assume 22.3 mmol; see step(iv) above) was added dropwise to HCl/EtOH (500 mL). The reactionmixture was stirred 15 h, then partially concentrated in vacuo yieldingthe sub-title compound as a liquid, which was used in step (vi) withoutfurther purification or characterization.

(vi) Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(O)OEt

Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(NH)OEt (6.24 g, assume 22.3 mmol; seestep (v) above) was dissolved in THF (250 mL), 0.5M H₂SO₄ (400 mL) wasadded and the reaction was stirred at 40° C. for 65 h, cooled and thenpartially concentrated in vacuo to remove most of the THF. The reactionmixture was then extracted with Et₂O (3×100 mL), dried (Na₂SO₄),filtered and concentrated in vacuo to afford the sub-title compound as asolid, which was used in step (vii) without further purification orcharacterization.

(vii) Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(O)OH

A solution of Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(O)OEt (6.25 g, assume 22.3mmol; see step (vi) above) in 2-propanol (175 mL) and 20% KOH (350 mL)was stirred at room temperature 15 h. The reaction was then partiallyconcentrated in vacuo to remove most of the 2-propanol. The remainingmixture was acidified with 1M H₂SO₄, extracted with Et₂O (3×100 mL),dried (Na₂SO₄) and concentrated in vacuo to give a solid. Flashchromatography on silica gel eluting with CHCl₃:MeOH:concentrated NH₄OH(6:3:1) afforded the ammonium salt of the sub-title compound. Theammonium salt was then dissolved in a mixture of EtOAc (75 mL) and H₂O(75 mL) and acidified with 2N HCl. The organic layer was separated andwashed with brine (50 mL), dried (Na₂SO₄) and concentrated in vacuo toafford the sub-title compound (3.2 g, 57% from steps (iv) to (vii)).

¹H NMR (300 MHz, CD₃OD) δ 7.38 (s, 1H), 7.22 (s, 1H), 7.15 (s, 1H), 6.89(t, J_(H-F)=71.1 Hz, 1H), 5.16 (s, 1H)

(viii) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)OH (a) andPh(3-Cl)(5-OCHF₂)-(S)CH(OAc)C(O)OH (b)

A mixture of Ph(3-Cl)(5-OCHF₂)—(R,S)CH(OH)C(O)OH (3.2 g, 12.7 mmol; seestep (vii) above) and Lipase PS “Amano” (˜2.0 g) in vinyl acetate (125mL) and MTBE (125 mL) was heated at reflux for 48 h. The reactionmixture was cooled, filtered through Celite® and the filter cake washedwith EtOAc. The filtrate was concentrated in vacuo and subjected toflash chromatography on silica gel eluting with CHCl₃:MeOH:concentratedNH₄OH (6:3:1) yielding the ammonium salts of the sub-title compounds (a)and (b). Compound (a) as a salt was dissolved in H₂O, acidified with 2NHCl and extracted with EtOAc. The organic layer was washed with brine,dried (Na₂SO₄), filtered and concentrated in vacuo to afford thesub-title compound (a) (1.2 g, 37%).

For sub-title compound (a)

¹H NMR (300 MHz, CD₃OD) δ 7.38 (s, 1H), 7.22 (s, 1H), 7.15 (s, 1H), 6.89(t, J_(H-F)=71.1 Hz, 1H), 5.17 (s, 1H)

(ix) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(Teoc)

To a solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)OH (1.1 g, 4.4 mmol; seestep (viii) above) and H-Aze-Pab(Teoc) (see international patentapplication WO 00/42059, 2.6 g, 5.7 mmol) in DMF (50 mL) at 0° C. wasadded PyBOP (2.8 g, 5.3 mmol) and collidine (1.3 g, 10.6 mmol). Thereaction was stirred at 0° C. for 2 h and then at room temperature foran additional 15 h. The reaction mixture was concentrated in vacuo andflash chromatographed on silica gel (3×), eluting first with CHCl₃:EtOH(9:1), then with EtOAc:EtOH (20:1) and finally eluting with CH₂Cl₂:CH₃OH(95:5) to afford the sub-title compound (1.0 g, 37%) as a whiteamorphous solid.

¹H NMR (300 MHz, CD₃OD, mixture of rotamers) δ 7.79-7.85 (d, J=8.7 Hz,2H), 7.15-7.48 (m, 5H), 6.89 and 6.91 (t, J_(H-F)=71.1 Hz, 1H), 5.12 and5.20 (s, 1H), 4.75-4.85 (m, 1H), 3.97-4.55 (m, 6H), 2.10-2.75 (m, 2H),1.05-1.15 (m, 2H), 0.09 (s, 9H) MS (m/z) 611 (M+1)⁺

(x) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(OMe, Teoc)

Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(Teoc) (0.40 g, 0.65 mmol; seestep (ix) above), was dissolved in 20 mL of acetonitrile and 0.50 g (6.0mmol) of O-methyl hydroxylamine hydrochloride was added. The mixture washeated at 70° C. for 2 h. The solvent was evaporated and the residue waspartitioned between water and ethyl acetate. The aqueous phase wasextracted twice more with ethyl acetate and the combined organic phasewas washed with water, brine, dried (Na₂SO₄), filtered and evaporated.Yield: 0.41 g (91%).

¹H-NMR (400 MHz; CDCl₃): δ 7.83 (bt, 1H), 7.57 (bs, 1H), 7.47 (d, 2H),7.30 (d, 2H), 7.20 (m, 1H), 7.14 (m, 1H), 7.01 (m, 1H), 6.53 (t, 1H),4.89 (s, 1H), 4.87 (m, 1H), 4.47 (m, 2H), 4.4-4.2 (b, 1H), 4.17-4.1 (m,3H), 3.95 (s, 3H), 3.67 (m, 1H), 2.68 (m, 1H), 2.42 (m,1H) 0.97 (m, 2H),0.01 (s, 9H).

(xi) Compound A

Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(OMe, Teoc) (0.40 g, 0.62 mmol;see step (x) above), was dissolved in 5 mL of TFA and allowed to reactfor 30 min. TFA was evaporated and the residue was partitioned betweenethyl acetate and NaHCO₃ (aq.). The aqueous phase was extracted twicemore with ethyl acetate and the combined organic phase was washed withwater, brine, dried (Na₂SO₄), filtered and evaporated. The product wasfreeze dried from water/acetonitrile. No purification was necessary.Yield: 0.28 g (85%).

¹H-NMR (600 MHz; CDCl₃): δ 7.89 (bt, 1H), 7.57 (d, 2H), 7.28 (d, 2H),7.18 (m, 1H), 7.13 (m,1H), 6.99 (m, 1H), 6.51 (t, 1H), 4.88 (s, 1H),4.87 (m, 1H), 4.80 (bs, 2H), 4.48 (dd, 1H), 4.43 (dd, 1H), 4.10 (m, 1H),3.89 (s, 3H), 3.68 (m, 1H), 2.68 (m, 1H), 2.40 (m, 1H).

¹³C-NMR (125 MHz; CDCl₃): (carbonyl and/or amidine carbons, rotamers) δ172.9, 170.8, 152.7, 152.6

HRMS calculated for C₂₂H₂₃ClF₂N₄O₅ (M−H)⁻ 495.1242, found 495.1247

Preparation B: Preparation of Compound B

(i) 2,6-Difluoro-4[(methylsulfinyl)(methylthio)methyl]benzonitrile

(Methylsulfinyl)(methylthio)methane (7.26 g, 0.0584 mol) was dissolvedin 100 mL of dry THF under argon and was cooled to −78° C. Butyllithiumin hexane (16 mL 1.6M, 0.0256 mol) was added dropwise with stirring. Themixture was stirred for 15 min. Meanwhile, a solution of3,4,5-trifluorobenzonitrile (4.0 g, 0.025 mmol) in 100 mL of dry THF wascooled to −78° C. under argon and the former solution was added througha cannula to the latter solution over a period of 35 min. After 30 min,the cooling bath was removed and when the reaction had reached roomtemperature it was poured into 400 mL of water. The THF was evaporatedand the remaining aqueous layer was extracted three times with diethylether. The combined ether phase was washed with water, dried (Na₂SO₄)and evaporated. Yield: 2.0 g (30%).

¹H NMR (500 MHz, CDCl₃) δ 7.4-7.25 (m, 2H), 5.01 (s, 1H, diasteromer),4.91 (s, 1H, diasteromer), 2.88 (s, 3H, diasteromer), 2.52 (s, 3H,diasteromer), 2.49 (s, 3H, diasteromer), 2.34 (s, 3H, diasteromer), 1.72(broad, 1H)

(ii) 2,6-Difluoro-4-formylbenzonitrile

2,6-Difluoro-4[(methylsulfinyl)(methylthio)methyl]benzonitrile (2.17 g,8.32 mmol; see step (i) above) was dissolved in 90 mL of THF and 3.5 mLof concentrated sulfuric acid was added. The mixture was left at roomtemperature for 3 days and subsequently poured into 450 mL of water.Extraction three times with EtOAc followed and the combined etherealphase was washed twice with aqueous sodium bicarbonate and with brine,dried (Na₂SO₄) and evaporated. Yield: 1.36 g (98%). The position of theformyl group was established by ¹³C NMR. The signal from the fluorinatedcarbons at 162.7 ppm exhibited the expected coupling pattern with twocoupling constants in the order of 260 Hz and 6.3 Hz respectivelycorresponding to an ipso and a meta coupling from the fluorine atoms.

¹H NMR (400 MHz, CDCl₃) δ 10.35 (s, 1H), 7.33 (m, 2H)

(iii) 2,6-Difluoro-4-hydroxymethylbenzonitrile

2,6-Difluoro-4-formylbenzonitrile (1.36 g, 8.13 mmol; see step (ii)above) was dissolved in 25 mL of methanol and cooled on an ice bath.Sodium borohydride (0.307 g, 8.12 mmol) was added in portions withstirring and the reaction was left for 65 min. The solvent wasevaporated and the residue was partitioned between diethyl ether andaqueous sodium bicarbonate. The ethereal layer was washed with moreaqueous sodium bicarbonate and brine, dried (Na₂SO₄) and evaporated. Thecrude product crystallised soon and could be used without furtherpurification. Yield: 1.24 g (90%).

¹H NMR (400 MHz, CDCl₃) δ 7.24 (m, 2H), 4.81 (s, 2H), 2.10 (broad, 1H)

(iv) 4-Cyano-2,6-difluorobenzyl methanesulfonate

To an ice cooled solution of 2,6-difluoro-4-hydroxymethylbenzonitrile(1.24 g, 7.32 mmol; see step (iii) above) and methanesulfonyl chloride(0.93 g, 8.1 mmol) in 60 mL of methylene chloride was addedtriethylamine (0.81 g, 8.1 mmol) with stirring. After 3 h at 0° C., themixture was washed twice with 1M HCl and once with water, dried (Na₂SO₄)and evaporated. The product could be used without further purification.Yield: 1.61 g (89%).

¹H NMR (300 MHz, CDCl₃) δ 7.29 (m, 2H), 5.33 (s, 2H), 3.07 (s, 3H)

(v) 4-Azidomethyl-2,6-difluorobenzonitrile

A mixture of 4-cyano-2,6-difluorobenzyl methanesulfonate (1.61 g, 6.51mmol; see step (iv) above) and sodium azide (0.72 g, 0.0111 mol) in 10mL of water and 20 mL of DMF was stirred at room temperature overnight.The resultant was subsequently poured into 200 mL of water and extractedthree times with diethyl ether. The combined ethereal phase was washedfive times with water, dried (Na₂SO₄) and evaporated. A small sample wasevaporated for NMR purposes and the product crystallised. The rest wasevaporated cautiously but not until complete dryness. Yield(theoretically 1.26 g) was assumed to be almost quantitative based onNMR and analytical HPLC.

¹H NMR (400 MHz, CDCl₃) δ 7.29 (m, 2H), 4.46 (s, 2H)

(vi) 4-Aminomethyl-2,6-difluorobenzonitrile

This reaction was carried out according to the procedure described in J.Chem. Res. (M) (1992) 3128. To a suspension of 520 mg of 10% Pd/C (50%moisture) in 20 mL of water was added a solution of sodium borohydride(0.834 g, 0.0221 mol) in 20 mL of water. Some gas evolution resulted.4-Azidomethyl-2,6-difluorobenzonitrile (1.26 g, 6.49 mmol; see step (v)above) was dissolved in 50 mL of THF and added to the aqueous mixture onan ice bath over 15 min. The mixture was stirred for 4 h, whereafter 20mL of 2M HCl was added and the mixture was filtered through Celite. TheCelite was rinsed with more water and the combined aqueous phase waswashed with EtOAc and subsequently made alkaline with 2M NaOH.Extraction three times with methylene chloride followed and the combinedorganic phase was washed with water, dried (Na₂SO₄) and evaporated.Yield: 0.87 g (80%).

¹H NMR (400 MHz, CDCl₃) δ 7.20 (m, 2H), 3.96 (s, 2H), 1.51 (broad, 2H)

(vii) 2,6-Difluoro-4-tert-butoxycarbonylaminomethylbenzonitrile

A solution of 4-aminomethyl-2,6-difluorobenzonitrile (0.876 g, 5.21mmol; see step (vi) above) was dissolved in 50 mL of THF anddi-tert-butyl dicarbonate (1.14 g, 5.22 mmol) in 10 mL of THF was added.The mixture was stirred for 3.5 h. The THF was evaporated and theresidue was partitioned between water and EtOAc. The organic layer waswashed three times with 0.5 M HCl and water, dried (Na₂SO₄) andevaporated. The product could be used without further purification.Yield: 1.38 g (99%).

¹H NMR (300 MHz, CDCl₃) δ 7.21 (m,2H), 4.95 (broad, 1H), 4.43 (broad,2H), 1.52 (s, 9H)

(viii) Boc-Pab(2,6-diF)(OH)

A mixture of 2,6-difluoro-4-tert-butoxycarbonylaminomethylbenzonitrile(1.38 g, 5.16 mmol; see step (vii) above), hydroxylamine hydrochloride(1.08 g, 0.0155 mol) and triethylamine (1.57 g, 0.0155 mol) in 20 mL ofethanol was stirred at room temperature for 36 h. The solvent wasevaporated and the residue was partitioned between water and methylenechloride. The organic layer was washed with water, dried (Na₂SO₄) andevaporated. The product could be used without further purification.Yield: 1.43 g (92%).

¹H NMR (500 MHz, CD₃OD) δ 7.14 (m, 2H), 4.97 (broad, 1H), 4.84 (broad,2H), 4.40 (broad, 2H), 1.43 (s, 9H)

(ix) Boc-Pab(2,6-diF) x HOAc

This reaction was carried out according to the procedure described byJudkins et al, Synth. Comm. (1998) 4351. Boc-Pab(2,6-diF)(OH) (1.32 g,4.37 mmol; see step (viii) above), acetic anhydride (0.477 g, 4.68 mmol)and 442 mg of 10% Pd/C (50% moisture) in 100 mL of acetic acid washydrogenated at 5 atm pressure for 3.5 h. The mixture was filteredthrough Celite, rinsed with ethanol and evaporated. The residue wasfreeze-dried from acetonitrile and water and a few drops of ethanol. Thesub-title product could be used without further purification. Yield:1.49 g (99%).

1H NMR (400 MHz, CD₃OD) δ 7.45 (m, 2H), 4.34 (s, 2H), 1.90 (s, 3H), 1.40(s, 9H)

(x) Boc-Pab(2,6-diF)(Teoc)

To a solution of Boc-Pab(2,6-diF) x HOAc (1.56 g, 5.49 mmol; see step(ix) above) in 100 mL of THF and 1 mL of water was added2-(trimethylsilyl)ethyl p-nitrophenyl carbonate (1.67 g, 5.89 mmol). Asolution of potassium carbonate (1.57 g, 0.0114 mol) in 20 mL of waterwas added dropwise over 5 min. The mixture was stirred overnight. TheTHF was evaporated and the residue was partitioned between water andmethylene chloride. The aqueous layer was extracted with methylenechloride and the combined organic phase was washed twice with aqueoussodium bicarbonate, dried (Na₂SO₄) and evaporated. Flash chromatographyon silica gel with heptane/EtOAc=2/1 gave 1.71 g (73%) of pure compound.

¹H NMR (400 MHz, CDCl₃) δ 7.43 (m, 2H), 4.97 (broad, 1H), 4.41 (broad,2H), 4.24 (m, 2H), 1.41 (s, 9H), 1.11 (m, 2H), 0.06 (s, 9H)

(xi) Boc-Aze-Pab(2,6-diF)(Teoc)

Boc-Pab(2,6-diF)(Teoc) (1.009 g, 2.35 mmol; see step (x) above) wasdissolved in 50 mL of EtOAc saturated with HCl(g). The mixture was leftfor 10 min., evaporated and dissolved in 18 mL of DMF, and then cooledon an ice bath. Boc-Aze-OH (0.450 g, 2.24 mmol), PyBOP (1.24 g, 2.35mmol) and lastly diisopropylethyl amine (1.158 g, 8.96 mmol) were added.The reaction mixture was stirred for 2 h and then poured into 350 mL ofwater and extracted three times with EtOAc. The combined organic phasewas washed with brine, dried (Na₂SO₄) and evaporated. Flashchromatography on silica gel with heptane:EtOAc (1:3) gave 1.097 g (96%)of the desired compound.

¹H NMR (500 MHz, CDCl₃) δ 7.46 (m, 2H), 4.65-4.5 (m, 3H), 4.23 (m, 2H),3.87 (m, 1H), 3.74 (m, 1H), 2.45-2.3 (m, 2H), 1.40 (s, 9H), 1.10 (m,2H), 0.05 (s, 9H)

(xii) Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(Teoc)

Boc-Aze-Pab(2,6-diF)(Teoc) (0.256 g, 0.500 mmol; see step (xi) above)was dissolved in 20 mL of EtOAc saturated with HCl(g). The mixture wasleft for 10 min. and evaporated and dissolved in 5 mL of DMF.Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)OH (0.120 g, 0.475 mmol; see PreparationA(viii) above), PyBOP (0.263 g, 0.498 mmol) and lastly diisopropylethylamine (0.245 g, 1.89 mmol) were added. The reaction mixture was stirredfor 2 h and then poured into 350 mL of water and extracted three timeswith EtOAc. The combined organic phase was washed with brine, dried(Na₂SO₄) and evaporated. Flash chromatography on silica gel with EtOAcgave 0.184 g (60%) of the desired sub-title compound.

¹H NMR (400 MHz, CD₃OD, mixture of rotamers) δ 7.55-7.45 (m, 2H), 7.32(m, 1H, major rotamer), 7.27 (m, 1H, minor rotamer), 7.2-7.1 (m, 2H),6.90 (t, 1H, major rotamer), 6.86 (t, 1H, minor rotamer), 5.15 (s, 1H,major rotamer), 5.12 (m, 1H, minor rotamer), 5.06 (s, 1H, minorrotamer), 4.72 (m, 1H, major rotamer), 4.6-4.45 (m, 2H), 4.30 (m, 1H,major rotamer), 4.24 (m, 2H), 4.13 (m, 1H, major rotamer), 4.04 (m, 1H,minor rotamer), 3.95 (m, 1H, minor rotamer), 2.62 (m, 1H, minorrotamer), 2.48 (m, 1H, major rotamer), 2.22 (m, 1H, major rotamer), 2.10(m, 1H, minor rotamer), 1.07 (m, 2H), 0.07 (m, 9H)

(xiii) Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(OMe,Teoc)

A mixture of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(Teoc) (64mg, 0.099 mmol; see step (xii) above) and O-methyl hydroxylaminehydrochloride (50 mg, 0.60 mmol) in 4 mL of acetonitrile was heated at70° C. for 3 h. The solvent was evaporated and the residue waspartitioned between water and EtOAc. The aqueous layer was extractedtwice with EtOAc and the combined organic phase was washed with water,dried (Na₂SO₄) and evaporated. The product could be used without furtherpurification. Yield: 58 mg (87%).

¹H NMR (400 MHz, CDCl₃) δ 7.90 (bt, 1H), 7.46 (m, 1H), 7.25-6.95 (m,5H), 6.51, t, 1H), 4.88 (s, 1H), 4.83 (m, 1H), 4.6-4.5 (m, 2H), 4.4-3.9(m, 4H), 3.95 (s, 3H), 3.63 (m, 1H), 2.67 (m, 1H), 2.38 (m, 1H), 1.87(broad, 1H), 0.98 (m, 2H), 0.01, s, 9H)

(xiv) Compound B

Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(OMe,Teoc) (58 mg, 0.086mmol; see step (xiii) above) was dissolved in 3 mL of TFA, cooled on anice bath and allowed to react for 2 h. The TFA was evaporated and theresidue dissolved in EtOAc. The organic layer was washed twice withaqueous sodium carbonate and water, dried (Na₂SO₄) and evaporated. Theresidue was freeze-dried from water and acetonitrile to give 42 mg (92%)of the title compound.

¹H NMR (300 MHz, CDCl₃) δ 7.95 (bt, 1H), 7.2-7.1 (m, 4H), 6.99 (m, 1H),6.52 (t, 1H), 4.88 (s, 1H), 4.85-4.75 (m, 3H), 4.6-4.45 (m, 2H), 4.29(broad, 1H), 4.09 (m, 1H), 3.89 (s, 3H), 3.69 (m, 1H), 2.64 (m, 1H),2.38 (m, 1H), 1.85 (broad, 1H)

¹³C-NMR (100 MHz; CDCl₃): (carbonyl and/or amidine carbons) δ 172.1,169.8, 151.9

APCI-MS: (M+1)=533/535 m/z

Preparation C: Preparation of Compound C

(i) (2-Monofluoroethyl) methanesulfonate

To a magnetically stirred solution of 2-fluoroethanol (5.0 g, 78.0 mmol)in CH₂Cl₂ (90 mL) under nitrogen at 0° C. was added triethylamine (23.7g, 234 mmol) and methanesulfonyl chloride (10.7 g, 93.7 mmol). Themixture was stirred at 0° C. for 1.5 h, diluted with CH₂Cl₂ (100 mL) andwashed with 2N HCl (100 mL). The aqueous layer was extracted with CH₂Cl₂(50 mL) and the combined organic extracts washed with brine (75 mL),dried (Na₂SO₄), filtered and concentrated in vacuo to afford thesub-title compound (9.7 g, 88%) as a yellow oil which was used withoutfurther purification.

¹H NMR (300 MHz, CDCl₃) δ 4.76 (t, J=4 Hz, 1H), 4.64 (t, J=4 Hz, 1H),4.52 (t, J=4 Hz, 1H), 4.43 (t, J=4 Hz, 1H), 3.09 (s, 3H).

(ii) 3-Chloro-5-monofluoroethoxybenzaldehyde

To a solution of 3-chloro-5-hydroxybenzaldehyde (8.2 g, 52.5 mmol; seePreparation A(ii) above) and potassium carbonate (9.4 g, 68.2 mmol) inDMF (10 mL) under nitrogen was added a solution of (2-monofluoroethyl)methanesulfonate (9.7 g, 68.2 mmol; see step (i) above) in DMF (120 mL)dropwise at room temperature. The mixture was heated to 100° C. for 5 hand then stirred overnight at room temperature. The reaction was cooledto 0° C., poured into ice-cold 2N HCl and extracted with EtOAc. Thecombined organic extracts were washed with brine, dried (Na₂SO₄),filtered and concentrated in vacuo. The brown oil was chromatographed onsilica gel eluting with Hex:EtOAc (4:1) to afford the sub-title compound(7.6 g, 71%) as a yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 9.92 (s, 1H), 7.48 (s, 1H), 7.32 (s, 1H), 7.21(s, 1H), 4.87 (t, J=4 Hz, 1H), 4.71 (t, J=3 Hz, 1H), 4.33 (t, J=3 Hz,1H), 4.24 (t, J=3 Hz, 1H).

(iii) Ph(3-Cl)(5-OCH₂CH₂F)—(R,S)CH(OTMS)CN

To a solution of 3-chloro-5-monofluoroethoxybenzaldehyde (7.6 g, 37.5mmol; see step (ii) above) and zinc iodide (3.0 g, 9.38 mmol) in CH₂Cl₂(310 mL) was added trimethylsilyl cyanide (7.4 g, 75.0 mmol) dropwise at0° C. under nitrogen. The mixture was stirred at 0° C. for 3 h and atroom temperature overnight. The reaction was diluted with H₂O (300 mL),the organic layer was separated, dried (Na₂SO₄), filtered andconcentrated in vacuo to afford the sub-title compound (10.6 g, 94%) asa brown oil that was used without further purification orcharacterisation.

(iv) Ph(3-Cl)(5-OCH₂CH₂F)—(R,S)CH(OH)C(O)OH

Concentrated hydrochloric acid (100 mL) was added toPh(3-Cl)(5-OCH₂CH₂F)—(R,S)CH(OTMS)CN (10.6 g, 5.8 mmol; see step (iii)above) and the solution stirred at 100° C. for 3 h. After cooling toroom temperature, the reaction was further cooled to 0° C., basifiedslowly with 3N NaOH (˜300 mL) and washed with Et₂O (3×200 mL). Theaqueous layer was acidified with 2N HCl (80 mL) and extracted with EtOAc(3×300 mL). The combined EtOAc extracts were dried (Na₂SO₄), filteredand concentrated in vacuo to afford the sub-title compound (8.6 g, 98%)as a pale yellow solid that was used without further purification.

R_(f)=0.28 (90:8:2 CHCl₃:MeOH:concentrated NH₄OH)

¹H NMR (300 MHz, CD₃OD) δ 7.09 (s, 1H), 7.02 (s, 1H), 6.93 (s, 1H), 5.11(s, 1H), 4.77-4.81 (m, 1H), 4.62-4.65 (m, 1H), 4.25-4.28 (m, 1H),4.15-4.18 (m, 1H).

(v) Ph(3-Cl)(5-OCH₂CH₂F)-(S)CH(OAc)C(O)OH (a) andPh(3-Cl)(5-OCH₂CH₂F)—(R)CH(OH)C(O)OH (b)

A solution of Ph(3-Cl)(5-OCH₂CH₂F)—(R,S)CH(OH)C(O)OH (8.6 g, 34.5 mmol;see step (iv) above) and Lipase PS “Amano” (4.0 g) in vinyl acetate (250mL) and MTBE (250 mL) was heated at 70° C. under nitrogen for 3 d. Thereaction was cooled to room temperature and the enzyme removed byfiltration through Celite®. The filter cake was washed with EtOAc andthe filtrate concentrated in vacuo. Chromatography on silica gel elutingwith CHCl₃:MeOH:Et₃N (90:8:2) afforded the triethylamine salt ofsub-title compound (a) as a yellow oil. In addition, the triethylaminesalt of sub-title compound (b) (4.0 g) was obtained. The salt ofsub-title compound (b) was dissolved in H₂O (250 mL), acidified with 2NHCl and extracted with EtOAc (3×200 mL). The combined organic extractswere dried (Na₂SO₄), filtered and concentrated in vacuo to yield thesub-title compound (b) (2.8 g, 32%) as a yellow oil.

Data for Sub-Title Compound (b):

R_(f)=0.28 (90:8:2 CHCl₃:MeOH:concentrated NH₄OH)

¹H NMR (300 MHz, CD₃OD) δ 7.09 (s, 1H), 7.02 (s, 1H), 6.93 (s, 1H), 5.11(s, 1H), 4.77-4.81 (m, 1H), 4.62-4.65 (m, 1H), 4.25-4.28 (m, 1H),4.15-4.18 (m, 1H).

(vi) Compound C

To a solution of Ph(3-Cl)(5-OCH₂CH₂F)—(R)CH(OH)C(O)OH (818 mg, 3.29mmol; see step (v) above) in DMF (30 mL) under nitrogen at 0° C. wasadded HAze-Pab(OMe).2HCl (1.43 g, 4.27 mmol, see international patentapplication WO 00/42059), PyBOP (1.89 g, 3.68 mmol), and DIPEA (1.06 g,8.23 mmol). The reaction was stirred at 0° C. for 2 h and then at roomtemperature overnight. The mixture was concentrated in vacuo and theresidue chromatographed two times on silica gel, eluting first withCHCl₃:EtOH (15:1) and second with EtOAc:EtOH (20:1) to afford the titlecompound (880 mg, 54%).

R_(f)=0.60 (10:1 CHCl₃:EtOH)

¹H NMR (300 MHz, CD₃OD, complex mixture of rotamers) δ 7.58-7.60 (d, J=8Hz, 2H), 7.34 (d, J=7 Hz, 2H), 7.05-7.08 (m, 2H), 6.95-6.99 (m, 1H),5.08-5.13 (m, 1H), 4.77-4.82 (m, 1H), 4.60-4.68 (m, 1H), 3.99-4.51 (m,7H), 3.82 (s, 3H), 2.10-2.75 (m, 2H).

¹³C-NMR (150 MHz; CD₃OD): (carbonyl and/or amidine carbons) δ 173.3,170.8, 152.5.

APCI-MS: (M+1)=493 m/z.

EXAMPLES 1 and 2 Preparation of Salts of Compound A Example 1

General Method for Salt Preparation

The following generic method was employed to prepare salts of CompoundA: 200 mg of Compound A (see Preparation A above) was dissolved in 5 mLof MeOH. To this solution was added a solution of the relevant acid (1.0molar equivalent) dissolved in 5 mL of MeOH. After stirring for 10minutes at room temperature, the solvent was removed by way of a rotaryevaporator. The remaining solid material was re-dissolved in 8 mL ofacetonitrile:H₂O (1:1). Freeze-drying afforded colorless amorphousmaterial in each case.

Acids Employed:

-   (1S)-(+)-10-camphorsulfonic-   malic-   cyclohexylsulphamic-   phosphoric-   dimethylphosphoric-   p-toluenesulphonic-   L-lysine-   L-lysine hydrochloride-   saccharinic-   methanesulphonic-   hydrochloric

Appropriate characterising data are shown in Table 1. TABLE 1

ppm (MeOD) H18, H19, H24(see Mw Mw structure at end of Salt acid saltLRMS Example 9 below) (1S)-(+)-10- 232.20 729.20 230.9 7.57, 7.68, 3.97camphor- 495.1 sulfonate 497.0 727.3 maleate 116.07 612.97 114.8 7.45,7.64, 3.89 495.1 497.0 cyclohexyl- 179.24 676.14 177.9 7.44, 7.64, 3.89sulphamate 495.1 496.9 674.3 676.1 phosphate 97.99 594.89 495.1 7.37,7.61, 3.84 497.0 593.1 dimethyl- 126.05 622.95 124.9 7.50, 7.66, 3.92phosphate 495.1 497.0 621.2 623.0 p-toluene- 172.20 669.10 170.9 7.54,7.71, 3.95 sulphonate 495.1 497.0 L-lysine 146.19 643.09 145.0 7.36,7.60, 3.83 495.1 497.0 L-lysine 182.65 679.55 495.1 7.36, 7.60, 3.83hydrochloride 497.0 531.1 (HCl) saccharinate 183.19 680.09 181.9 7.44,7.64. 3.89 495.1 497.0 methane- 96.11 593.01 495.1 7.57, 7.68, 3.97sulphonate 497.0 591.2 593.1 hydrochloride 36.46 533.36 495.1 7.55,7.67, 3.95 496.9 531.1 532.5 535.2

All salts formed in this Example were amorphous.

Example 2

Further amorphous salts of Compound A were made using analogoustechniques to those described in Example 1 above from the followingacids:

-   hydrobromic acid (1:1 salt)-   hydrochloric acid (1:1 salt)-   sulphuric acid (1:0.5 salt)-   1,2-ethanedisulfonic acid (1:0.5 salt)-   1S-camphorsulfonic acid (1:1 salt)-   (+/−)-camphorsulfonic acid (1:1 salt)-   ethanesulfonic acid (1:1 salt)-   nitric acid (1:1 salt)-   toluenesulfonic acid (1:1 salt)-   methanesulfonic acid (1:1 salt)-   p-xylenesulfonic acid (1:1 salt)-   2-mesitylenesulfonic acid (1:1 salt)-   1,5-naphthalenesulfonic acid (1:0.5 salt)-   naphthalenesulfonic acid (1:1 salt)-   benzenesulfonic acid (1:1 salt)-   saccharinic acid (1:1 salt)-   maleic acid (1:1 salt)-   phosphoric acid (1:1 salt)-   D-glutamic acid (1:1 salt)-   L-glutamic acid (1:1 salt)-   D,L-glutamic acid (1:1 salt)-   L-arginine (1:1 salt)-   L-lysine (1:1 salt)-   L-lysine hydrochloride (1:1 salt)-   glycine (1:1 salt)-   salicylic acid (1:1 salt)-   tartaric acid (1:1 salt)-   fumaric acid (1:1 salt)-   citric acid (1:1 salt)-   L-(−)-malic acid (1:1 salt)-   D,L-malic acid (1:1 salt)-   D-gluconic acid (1:1 salt)

EXAMPLE 3 Preparation of Amorphous Compound A, Ethanesulfonic Acid Salt

Compound A (203 mg; see Preparation A above) was dissolved in ethanol (3mL) and ethanesulfonic acid (1 eq., 95%, 35 μL) was added to thesolution. The mixture was stirred for a few minutes, and then thesolvent was evaporated. The resulting oil was slurried in iso-octane andevaporated to dryness until a solid material was obtained. Finally, thesubstance was re-slurried in iso-octane and the solvent evaporated againresulting in a white, dry, amorphous solid. The substance was vacuumdried at 40° C. overnight.

EXAMPLES 4 to 9 Preparation of Crystalline Compound A, EthanesulfonicAcid Salt Example 4

Crystallisation of Amorphous Material

Amorphous Compound A, ethanesulfonic acid salt (17.8 mg; see Example 3above) was slurried in methyl iso-butyl ketone (600 μL). After 1 week,crystalline needles were observed, which were filtered off andair-dried.

Examples 5 to 7

Reaction Crystallisations (without Anti-Solvent)

Example 5

Compound A (277 mg; see Preparation A above) was dissolved in methyliso-butyl ketone (3.1 mL). Ethanesulfonic acid was added (1 eq., 95%, 48μLL). Precipitation of amorphous ethanesulfonate salt occurredimmediately. More methyl iso-butyl ketone (6 mL) was added and theslurry was treated with ultrasound. Finally, a third portion of methyliso-butyl ketone (3.6 mL) was added and then the slurry was leftovernight with stirring (magnetic stirrer). The next day, the substancehad transformed into crystalline needles. The slurry was filtered off,washed with methyl iso-butyl ketone (0.5 mL) and air dried.

Example 6

Compound A (236 mg; see Preparation A above) was dissolved at roomtemperature in methyl iso-butyl ketone (7 mL). Ethanesulfonic acid (1eq., 41 μL) was mixed with 2 mL of methyl iso-butyl ketone in a vial.The solution of Compound A was seeded with crystalline Compound A,ethanesulfonic acid salt (see Examples 4 and 5 above). Then, 250 μL ofthe methyl iso-butyl ketone solution of ethanesulfonic acid was added inportions over 45 minutes. The solution was seeded again, and thetemperature was increased to 30° C. Then, 500 μL of the methyl iso-butylketone solution was added over approximately 1 hour. The resultingslurry was left overnight before a final amount of the methyl iso-butylketone/acid solution was added over 20 minutes. The vial was rinsed with1.5 mL of methyl iso-butyl ketone, which was added to the slurry. Aftera further 6 hours, the crystals were filtered off, washed with methyliso-butyl ketone (2 mL) and dried under reduced pressure at 40° C. Atotal of 258 mg of crystalline salt was obtained which corresponds to ayield of approximately 87%.

Example 7

Compound A (2.36 g; see Preparation A above) was dissolved in methyliso-butyl ketone (90 mL). Seed crystals (10 mg) of Compound A,ethanesulfonic acid salt (see Examples 4 to 6 above) were added to thesolution, and then ethanesulfonic acid (40 μL) was added in twoportions. Further seed crystals (12 mg) and two portions ofethanesulfonic acid (2×20 μL) were then added. The slurry was dilutedwith methyl iso-butyl ketone (15 mL) before the addition ofethanesulfonic acid was continued. A total amount of 330 μLethanesulfonic acid was added, in portions, over 1 hour. A small amountof seed crystals was added and, finally, the slurry was left overnightwith stirring. The next day, the crystals were filtered off, washed withmethyl iso-butyl ketone (2×6 mL) and dried under reduced pressure at 40°C. After drying, a total of 2.57 g of white, crystalline product wasobtained corresponding to a yield of 89%.

Examples 8 and 9

Reaction Crystallizations (with Anti-Solvent)

Example 8

Compound A (163 mg; see Preparation A above) was dissolved iniso-propanol (1.2 mL). The solution was heated to 35° C. Ethanesulfonicacid was added (28 μL). Then, ethyl acetate (4.8 mL) was added and thesolution was seeded with crystalline Compound A, ethanesulphonic acidsalt (see Examples 4 to 7 above). Crystallization started almostimmediately. The slurry was left for about 80 minutes at 35° C. beforebeing allowed to cool to ambient temperature (21° C.). Two hours later,the crystals were filtered off, washed three times with ethyl acetate(3×0.4 mL), and dried under reduced pressure at 40° C. A total of 170 mgof crystalline title product was obtained which corresponds to a yieldof approximately 82%.

Example 9

Compound A (20.0 g; see Preparation A above) was dissolved iniso-propanol (146.6 mL) at 40° C. and ethanesulfonic acid (3.46 mL, 95%,1 eq.) was added to the solution. To the resulting clear solution, seedcrystals of Compound A, ethanesulfonic acid salt were added (50 mg; seeExamples 4 to 8 above). Then, ethyl acetate (234 mL) was added over 10minutes. The resulting slightly opaque solution was seeded once more (70mg) and left for one hour at 40° C. with stirring to allow forcrystallization to start. After this, a total of 352 mL of ethyl acetatewas added at a constant rate over one hour. When all of the ethylacetate had been added, the slurry was left for 1 hour, before beingcooled to 21° C. over 2 hours. The crystallization was allowed tocontinue for 1 hour at 21° C. before the crystals were filtered off,washed twice with ethyl acetate (50 mL+60 mL) and finally, dried underreduced pressure at 40° C. overnight. A total of 21.6 g of a white,crystalline salt was obtained, corresponding to a yield of approximately90%.

Compound A, ethanesulfonic acid salt was characterised by NMR asfollows: 23 mg of the salt was dissolved in deuterated methanol (0.7 mL)troscopy.

A combination of 1D (¹H, ¹³C and selective NOE) and 2D (gCOSY, gHSQC andgHMBC) NMR experiments were used. All data were in good agreement withthe theoretical structure of the salt, shown below. The molecule existsin two conformations in methanol. Based on the integral of the peakassigned to H5 (dominant conformer) and peak assigned to H5′ (otherconformer), the ratio between the two conformers was found to be 70:30.H22 could not be observed as these protons were in fast exchange withthe solvent CD₃OD.

Both the proton and the carbon resonance corresponding to position 1 aresplit due to the spin-coupling with the two fluorine nuclei in thatposition. The coupling constants are ²J_(HF)=73 Hz and ¹J_(CF)=263 Hz.

¹H and ¹³C NMR chemical shift assignment and proton-proton correlationsare shown in Table 2. TABLE 2 Atom ¹³C shift/ ¹H shift/ppm^(b) and No.Type ppm^(a) multiplicity^(c) J_(HH)/Hz  1 CH 117.5^(e) 6.90 (t) 73(²J_(HF))  1′ 117.5^(e) 6.88 (t)  2 C 153.5  2′ 153.5  3 CH 120.0 7.15(s)  3′ 119.7 7.13 (s)  4 C 136.2  4′ 135.9  5 CH 125.0 7.36 (s)  5′124.9 7.31 (s)  6 C 144.5  6′ 145.3  7 CH 117.3 7.20 (s)  7′ 117.2 7.15(s)  8 CH  72.0 5.20 (s)  8′  74.0 5.12 (s)  9 CO 173.1  9′ 173.8  11CH₂  51.6 a: 4.38 (m) b: 4.21 (m)  11′  49.0 a: 4.06 (m) b: 3.99 (m)  12CH₂  21.7 a: 2.55 (m) b: 2.29 (m)  12′  23.2 a: 2.70 (m) b: 2.15 (m)  13CH  63.1 4.80 (m)  13′  66.2 5.22 (m)  14 CO 172.9  14′ 173.6  15 NH8.76 (t, br) 5.2  15′ 8.79 (t, br) 5.2  16 CH₂  43.5 4.59 (AB-pattern)15.9 4.46 (AB-pattern) 15.9  16′  43.6 4.53 (AB-pattern) 15.9 4.49(AB-pattern) 15.9  17 C 146.9  17′ 147.0  18 CH 129.1 7.56 (d) 7.8  18′129.1 7.57 (d) 7.8  19 CH 129.2 7.67 (d) 7.8  19′ 129.4 7.70 (d) 7.8  20C 124.9 —  20′ 124.9  21 C 162.4  21′ 162.3  22 NH₂ Not observed  24 CH₃ 64.8 3.96 (s) 101 CH3 1.28 (t) 7.4 102 CH2 2.77 (m) 7.4^(a)Relative to the solvent resonance at 49.0 ppm.^(b)Relative to the solvent resonance at 3.30 ppm.^(c)s = singlet, t = triplet, m = multiplet, br = broad, d = doublet^(d)Obtained in the gCOSY experiment.^(e)The resonance is a triplet due to coupling with the two fluorinenuclei.¹J_(CF) = 263 Hz.

HRMS calculated for C₂₄H₂₉ClF₂N₄O₈S (M−H)⁻ 605.1284, found 605.1296.

Crystals of Compound A, ethanesulfonic acid salt (obtained by way of oneor more of Examples 4 to 9 above) were analyzed by XRPD and the resultsare tabulated below (Table 3) and are shown in FIG. 1. TABLE 3 d value(Å) Intensity (%) Intensity 16.5 10 m 12.2 74 vs 11.0 4 w 9.0 33 s 8.3 3vw 7.6 6 w 6.4 4 w 6.2 12 m 6.0 7 m 5.9 10 m 5.5 15 m 5.4 100 vs 5.1 7 m4.66 29 s 4.60 36 s 4.31 57 s 4.25 18 m 4.19 20 m 4.13 12 m 4.00 12 m3.87 13 m 3.83 6 w 3.76 7 m 3.72 6 w 3.57 9 m 3.51 7 m 3.47 5 w 3.39 3vw 3.31 11 m 3.26 10 m 3.21 8 m 3.16 4 w 3.03 8 m 2.78 4 w 2.74 5 w 2.673 vw 2.56 5 w 2.50 5 w 2.46 7 m 2.34 4 w 2.21 5 w 2.00 3 vw 1.98 3 vw

DSC showed an endotherm with an extrapolated melting onset temperatureof ca. 131° C. TGA showed a decrease in mass of ca. 0.2% (w/w) aroundthe melting point. DSC analysis repeated with a sample of lower solventcontent showed a melting onset temperature of ca. 144° C.

EXAMPLE 10 Preparation of Amorphous Compound A, Benzenesulfonic AcidSalt

Compound A (199 mg; see Preparation A above) was dissolved in ethanol (2mL). Benzenesulfonic acid (1 eq. 90%, 70 mg) was dissolved in ethanol (1mL) in a vial. The ethanol solution of the acid was added to thesolution of Compound A and the vial was rinsed with 1 mL ethanol, whichwas then added to the mixture. The mixture was stirred for a fewminutes, and then the ethanol was evaporated until an oil was formed.Ethyl acetate (3 mL) was added and the solvent was evaporated again todryness. An amorphous solid was formed.

EXAMPLES 11 to 13 Preparation of Crystalline Compound A, BenzenesulfonicAcid Salt Example 11

Crystallisation of Amorphous Material

Amorphous Compound A benzenesulfonic acid salt (20.7 mg; see Example 10above) was slurried in ethyl acetate (600 μL). After 5 days, crystallineneedles were observed in the slurry.

Examples 12 and 13

Reaction Crystallisations

Example 12

Compound A (128 mg; see Preparation A above) was dissolved in ethylacetate (3 mL). The solution was seeded with the slurry from Example 11above. Then, benzenesulfonic acid was added (1 eq., 90%, 45 mg).Precipitation of benzenesulphonic acid salt occurred immediately.iso-Propanol was added to the slurry (0.8 mL) and the mixture was seededagain. Two days later, the substance had transformed into crystallineneedles. The slurry was filtered off, washed with ethyl acetate (3×0.2mL) and dried for a short time under vacuum at 40° C. A total ofapproximately 140 mg of white solid was obtained.

Example 13

Compound A (246 mg; see Preparation A above) was dissolved iniso-propanol (1.52 mL). Benzenesulfonic acid was added (88 mg, 90%). Tothe clear solution, ethyl acetate was added (3 mL), and then the mixturewas seeded to initiate crystallisation. After 1 hour, more ethyl acetatewas added (2.77 mL). Finally, the slurry was allowed to crystalliseovernight before the crystals were filtered off, washed with ethylacetate (3×0.3 mL) and dried at 40° C. under vacuum. A total of 279 mgsalt was obtained which corresponds to a yield of approximately 86%.

Compound A, benzenesulfonic acid salt was characterised by NMR asfollows: 20 mg of the salt was dissolved in deuterated methanol (0.7mL). A combination of 1D (¹H, ¹³C and selective NOE) and 2D (gCOSY,gHSQC and gHMBC) NMR experiments were used. All data were in goodagreement with the theoretical structure of the salt, shown below. Themolecule exists in two conformations in methanol. Based on the integralof the peak assigned to H12 (dominant conformer) and peak assigned toH12′ (other conformer), the ratio between the two conformers was foundto be 70:30. H22 could not be observed as these protons were in fastexchange with the solvent CD₃OD.

Both the proton and the carbon resonance corresponding to position 1 aresplit due to the spin-coupling with the two fluorine nuclei in thatposition. The coupling constants are ²J_(HF)=74 Hz and ¹J_(CF)=260 Hz.

¹H and ¹³C NMR chemical shift assignment and proton-proton correlationsare shown in Table 4. TABLE 4 Atom ¹³C ¹H shift/ppm^(b) and No. Typeshift/ppm^(a) multiplicity^(c) J_(HH)/Hz  1 CH 117.5^(e) 6.89 (t) 74(²J_(HF))  1′ 117.5^(e) 6.87 (t)  2 C 153.5  2′ 153.5  3 CH 120.1 7.15(s)  3′ 119.7 7.12 (s)  4 C 136.2  4′ 135.9  5 CH 125.1 7.35 (s)  5′124.9 7.31 (s)  6 C 144.5  6′ 145.3  7 CH 117.3 7.20 (s)  7′ 117.2 7.14(s)  8 CH  72.8 5.20 (s)  8′  74.0 5.12 (s)  9 CO 173.1  9′ 173.8  11CH₂  51.6 a: 4.37 (m) b: 4.20 (m)  11′  49.0 a: 4.05 (m) b: 3.98 (m)  12CH₂  21.7 a: 2.53 (m) b: 2.28 (m)  12′  23.2 a: 2.69 (m) b: 2.14 (m)  13CH  63.1 4.79 (m)  13′  66.2 5.22 (m)  14 CO 172.9  14′ 173.6  15 NH8.75 (t, br) 5.3  15′ 8.78 (t, br) 5.3  16 CH₂  43.5 4.59 (AB-pattern)16.0 and 5.2 4.44 (AB-pattern) 16.0 and 4.8  16′  43.6 4.51 (AB-pattern)16.0 4.46 (AB-pattern) 16.0  17 C 146.9  17′ 147.0  18 CH 129.2 7.54 (d)8.3  18′ 129.2 7.56 (d) 8.3  19 CH 129.3 7.66 (d) 8.3  19′ 129.4 7.69(d) 8.3  20 C 124.9 —  20′ 124.9  21 C 162.4  21′ 162.4  22 NH₂ Notobserved  24 CH₃  64.8 3.95 (s) 101 CH 126.9 7.81 (m) 102 CH 129.1 7.41(m) 103 CH 131.2 7.42 (m) 104 C 146.4^(a)Relative to the solvent resonance at 49.0 ppm.^(b)Relative to the solvent resonance at 3.30 ppm.^(c)s = singlet, t = triplet, m = multiplet, br = broad, d = doublet.^(d)Obtained in the gCOSY experiment.^(e)The resonance is a triplet due to coupling with the two fluorinenuclei.¹J_(CF) = 260 Hz.^(f)connectivity difficult to determine due to overlap between resonance102 and 103

HRMS calculated for C₂₈H₂₉ClF₂N₄O₈S (M−H)⁻ 653.1284, found 653.1312.

Crystals of Compound A, benzenesulfonic acid salt (obtained by way ofone or more of Examples 11 to 13 above) were analyzed by XRPD and theresults are tabulated below (Table 5) and are shown in FIG. 2. TABLE 5 dvalue (Å) Intensity (%) Intensity 14.2 12 m 12.6 55 s 10.2 49 s 7.5 8 m6.4 5 w 6.3 30 s 6.1 5 w 5.9 100 vs 5.7 20 m 5.4 9 m 5.3 11 m 5.1 10 m4.96 3 vw 4.83 27 s 4.73 72 vs 4.54 23 s 4.50 10 m 4.35 28 s 4.30 38 s4.24 24 s 4.17 28 s 4.09 60 vs 4.08 61 vs 3.96 29 s 3.91 15 m 3.77 22 s3.62 11 m 3.52 20 m 3.31 44 s 3.19 8 m 3.15 11 m 3.09 8 m 3.00 7 m 2.893 vw 2.86 4 w 2.79 7 m 2.76 6 w 2.72 5 w 2.59 6 w 2.56 9 m 2.54 9 m 2.497 m 2.38 8 m 2.16 4 w 2.03 3 vw

DSC showed an endotherm with an extrapolated melting onset temperatureof ca. 152° C. TGA showed a decrease in mass of ca. 0.1% (w/w) aroundthe melting point.

EXAMPLE 14 Preparation of Amorphous Compound A, n-Propanesulfonic AcidSalt

Compound A (186 mg; see Preparation A above) was dissolved iniso-propanol (1.39 mL) and n-propanesulfonic acid (1 eq., 95%, 39 μL)was added. Ethyl acetate (5.6 mL) was added and the solvent wasevaporated until a dry, amorphous solid was formed.

EXAMPLES 15 and 16 Preparation of Crystalline Compound A,n-Propanesulfonic Acid Salt Example 15

Crystallisation of Amorphous Material

Amorphous Compound A, n-propanesulfonic acid salt (20 mg; see Example 14above) was dissolved in iso-propanol (60 μL) and iso-propyl acetate (180μL) was added. After three days crystalline needles were observed.

Example 16

Reaction Crystallisation

Compound A (229 mg; see Preparation A above) was dissolved iniso-propanol (1.43 mL). n-Propanesulfonic acid was added (1 eq., 95%, 48μL). Ethyl acetate was added (2 mL), and then the solution was seededwith crystalline salt from Example 15 above. Further ethyl acetate wasadded (5 mL) and the slurry was left overnight to crystallize. Thecrystals were filtered off, washed with ethyl acetate (3×0.3 mL) anddried under vacuum at 40° C.

Compound A, n-propanesulfonic acid salt was characterised by NMR asfollows: 13 mg of the salt was dissolved in deuterated methanol (0.7 mL)troscopy. A combination of 1D (¹H, ¹³C) and 2D (gCOSY) NMR experimentswere used. All data were in good agreement with the theoreticalstructure of the salt, shown below. The molecule exists in twoconformations in methanol. Based on the integral of the peak assigned toH12 (dominant conformer) and peak assigned to H12′ (other conformer),the ratio between the two conformers was found to be 65:35. H22 couldnot be observed as these protons were in fast exchange with the solventCD₃OD.

Both the proton and the carbon resonance corresponding to position 1 aresplit due to the spin-coupling with the two fluorine nuclei in thatposition. The coupling constants are ²J_(HF)=74 Hz and ¹J_(CF)=260 Hz.

¹H and ¹³C NMR chemical shift assignment and proton-proton correlationsare shown in Table 6. TABLE 6 Atom ¹H shift/ppm^(b) and No. Type ¹³Cshift/ppm^(a) multiplicity^(c) J_(HH)/Hz  1 CH 117.5^(e) 6.89 (t) 74(²J_(HF))  1′ 117.5^(e) 6.88 (t)  2 C 153.5  2′ 153.5  3 CH 120.0 7.16(s)  3′ 119.7 7.13 (s)  4 C 136.2  4′ 135.9  5 CH 125.1 7.36 (s)  5′124.9 7.31 (s)  6 C 144.5  6′ 145.3  7 CH 117.3 7.20 (s)  7′ 117.2 7.16(s)  8 CH  72.9 5.20 (s)  8′  74.1 5.12 (s)  9 CO 173.1  9′ 173.8  11CH₂  51.6 a: 4.37 (m) b: 4.20 (m)  11′  49.0 a: 4.06 (m) b: 3.98 (m)  12CH₂  21.7 a: 2.53 (m) b: 2.29 (m)  12′  23.2 a: 2.69 (m) b: 2.15 (m)  13CH  63.1 4.80 (m)  13′  66.2 5.22 (m)  14 CO 172.9  14′ 173.8  15 NH8.75 (t, br) 5.5  15′ 8.79 (t, br) 5.5  16 CH₂  43.5 4.59 (AB-pattern)16.0 and 6.6 4.45 (AB-pattern) 16.0 and 5.3  16′  43.6 4.51 4.50  17 C146.9  17′ 147.0  18 CH 129.1 7.54 (d) 8.5  18′ 129.2 7.57 (d) 8.5  19CH 129.2 7.67 (d) 8.5  19′ 129.4 7.69 (d) 8.5  20 C 124.9 —  20′ 124.9 21 C 162.4  21′ 162.4  22 NH₂ Not observed  24 CH₃  64.7 3.96 (s) 101CH  13.7 1.0 (t) 102 CH  19.6 1.78 (m) 103 CH  54.6 2.75 (m)^(a)Relative to the solvent resonance at 49.0 ppm.^(b)Relative to the solvent resonance at 3.30 ppm.^(c)s = singlet, t = triplet, m = multiplet, br = broad, d = doublet.^(d)Obtained in the gCOSY experiment.^(e)The resonance is a triplet due to coupling with the two fluorinenuclei.¹J_(CF) = 260 Hz.

HRMS calculated for C₂₅H₃₁ClF₂N₄O₈S (M−H)⁻ 619.1441, found 619.1436.

Crystals of Compound A, n-propanesulfonic acid salt (obtained by way ofone or more of Examples 15 and 16 above) were analyzed by XRPD and theresults are tabulated below (Table 7) and are shown in FIG. 3. TABLE 7 dvalue (Å) Intensity (%) Intensity 14.0 4 w 12.4 87 vs 10.0 30 s 8.0 3 vw7.5 7 m 7.0 0.6 vw 6.7 1 vw 6.4 1 vw 6.2 12 m 6.1 3 vw 5.8 100 vs 5.7 11m 5.5 3 vw 5.4 5 w 5.3 5 w 5.2 2 vw 5.1 3 vw 4.94 3 vw 4.78 21 s 4.68 42s 4.51 10 m 4.49 7 m 4.40 5 w 4.32 10 m 4.29 10 m 4.25 22 s 4.19 14 m4.14 15 m 4.07 23 s 4.04 20 m 3.94 16 m 3.88 10 m 3.73 15 m 3.65 2 vw3.59 3 vw 3.48 18 m 3.28 23 m 3.12 4 w 3.06 3 vw 2.97 6 w 2.84 2 vw 2.813 vw 2.76 2 vw 2.73 3 vw 2.70 2 vw 2.57 2 vw 2.54 6 w 2.51 6 w 2.46 8 m2.42 2 vw 2.39 3 vw 2.36 3 vw 2.32 2 vw 2.14 3 vw 2.01 2 vw

DSC showed an endotherm with an extrapolated melting onset temperatureof ca. 135° C. TGA showed no decrease in mass around the melting point.

EXAMPLE 17 Example 17-A

Preparation of Amorphous Compound A n-Butane Sulfonic Acid Salt

Amorphous Compound A (277 mg) was dissolved in IPA (1.77 ml) and butanesulfonic acid (approx. 1 eq. 70 μL) was added. Ethyl acetate (6 ml) wasadded and the solvent was evaporated until dry, amorphous solid wasformed.

Example 17-B

Preparation of Crystalline Compound A Butane Sulfonic Acid Salt

Amorphous Compound A butane sulfonic acid salt (71.5 mg; see preparationabove) was slurried in ethyl acetate (500 μl) over night. The crystalswere filtered off and were air-dried.

Compound A, butanesulfonic acid salt was charaterised by NMR as follows:

21.6 mg of the salt was dissolved in deuterated dimethylsulfoxide (0.7ml) and was investigated with ¹H and ¹³C NMR spectroscopy.

The spectra are very similar to other salts of the same compound and ingood agreement with the structure shown below. Most resonances in thespectra are present as sets of two peaks due to the slow rotation aroundthe C9-N10 bond, which results in two atropisomers that simultaneouslyexist in the solution. This is shown for other salts of the samecompound.

The two fluorine nuclei in position 1 give rise to split resonances forthe proton and the carbon in that position. The coupling constants are²J_(HF)=73 Hz and ¹J_(CF)=258 Hz.

Chemical shifts for protons and carbons are presented in Table 1.Protons in position 22 and 24 are not detected due to chemical exchange.There is a very broad hump between 8 and 9 ppm in the proton spectrumcorresponding to these protons. TABLE 8 ¹H and ¹³C NMR chemical shiftassignment of Compound A n-butanesulfonate salt in deuterateddimethylsulfoxide at 25° C. Atom ¹³C shift/ ¹H shift/ppm^(b) and No. Typppm^(a) multiplicity^(c) J_(HH)/Hz  1 CHF 116.3^(d) 7.29 (t) 73(²J_(HF))  1′ 2 116.3^(d) 7.28 (t) 73 (²J_(HF))  2 c 151.5 na na  2′151.3 na na  3 CH 118.0 7.25 (t)^(e) nd  3′ 117.6 7.21 (t)^(e) nd  4 C133.8 na na  4′ 133.4 na na  5 CH 123.8 7.34 (t)^(e) nd  5′ 123.6 7.25(t)^(e) nd  6 C 144.5 na na  6′ 145.2 na na  7 CH 116.3 7.19 (t)^(e) nd 7′ 116.1 7.12 (t)^(e) nd  8 CH  70.9 5.13 (s) na  8′  71.2 4.99 (s) na 9 CO 170.6 na na  9′ 171.1 na na 11 CH₂  50.0 a: 4.24 (m) b: 4.12 (m)nd 11′  46.9 3.85 (m) nd 12 CH₂  20.5 a: 2.41 (m) b: 2.10 (m) nd 12′ 21.7 a: 2.60 (m) b: 2.02 (m) nd 13 CH  61.2 4.65 (dd) 5.6 and 8.9 13′ 63.9 5.12 (m) nd 14 CO 170.2 na na 14′ 171.0 na na 16 CH₂  41.8 4.38(m) nd 16′  42.0 4.38 (m) nd 17 C 144.7 na na 18 CH 127.5 7.44 (d) 8.2127.6 7.44 nd 19 CH 127.8 7.66 (d) 8.2 20 C 125.1 na na 21 C 157.9 na na24 CH₃  63.3 3.83 (s) na 24′  63.3 3.82 (s) na 26 CH₂  51.4 2.41 (m) nd27 CH₂  27.3 1.52 (m) nd 28 CH₂  21.7 1.30 (m) nd 29 CH₃  14.0 0.83 (t)7.3^(a)Relative to the solvent resonance at 49.0 ppm.^(b)Relative to the solvent resonance at 3.30 ppm.^(c)s = singlet, d = doublet, dd = doublet of doublets, t = triplet, m =multiplet.^(d)The resonance is a triplet due to coupling with the two fluorinenuclei F1.¹JCF = 258 Hz.^(e)The ⁴J_(HH) coupling with the meta-protons is not fully resolved.na = not applicable,nd = not determined

HRMS calculated for C₂₆H₃₂ClF₂N₄O₈S (M−H)⁻ 633.1597, found 633.1600

Crystals of Compound A n-butanesulfonic acid salt (obtained as describedabove in Example 17-B) were analyzed by XRPD and the results aretabulated below (Table 9) and are shown in FIG. 4. TABLE 9 d-value (Å)Intensity (%) Intensity 14.3 8 m 12.8 81 vs 10.3 44 s 8.2 4 w 7.7 13 m6.7 2 vw 6.4 8 m 6.2 18 m 6.0 100 vs 5.8 29 s 5.6 4 w 5.4 11 m 5.3 16 m5.1 15 m 4.98 6.5 w 4.91 34 s 4.76 56 s 4.57 20 m 4.42 13 m 4.36 19 m4.30 45 s 4.18 42 s 4.13 88 vs 4.01 34 s 3.92 28 s 3.82 18 m 3.64 6.6 w3.58 16 m 3.47 5 w 3.44 6 w 3.38 12 m 3.35 32 s 3.32 22 s 3.29 12 m 3.208 m 3.17 9 m 3.02 12 m 2.90 6 w 2.81 3.9 vw 2.75 3 vw 2.64 3.5 vw 2.5910 m 2.57 8 m 2.50 4 w 2.45 5 w 2.40 6 w 2.31 3 vw

DSC showed an endotherm with an extrapolated melting onset temperatureof ca 118° C. and TGA showed an approximate 0.04% weight loss between 25and 150° C.

EXAMPLE 18 Preparation of Salts of Compound B Example 18-A

General Method for Salt Preparation

The following generic method was employed to prepare salts of CompoundB: 200 mg of compound B (see Preparation B above) was dissolved in 5 mLof MIBK (methyl isobutyl ketone). To this solution was added a solutionof the relevant acid (1.0 or 0.5 molar equivalent, as indicated in Table10) dissolved in 1.0 mL of MIBK. After stirring for 10 minutes at roomtemperature, the solvent was removed by way of a rotary evaporator. Theremaining solid material was re-dissolved in about 8 mL ofacetonitrile:H₂O (1:1). Freeze-drying afforded colorless amorphousmaterial in each case.

Acid Employed:

-   Esylate (ethanesulfonic acid)-   Besylate (benzene sulfonic acid)-   Cyclohexylsulphamate-   Sulphate-   Bromide-   p-Toluenesulphonate-   2-Naphtalenesulfonate-   Hemisulfate-   Methanesulphonate-   Nitrate-   Hydrochloride

Appropriate characterising data are shown in Table 10 TABLE 10 Salt Mwacid Mw salt MS ES− Esylate 110.13 643.01 108.8 531.1 641.0 Besylate158.18 691.06 156.8 531.1 689.2 Cyclohexyl- 179.24 712.12 177.9sulphamate 531.2 710.4 Sulphate 98.08 630.96 531.1 Bromide 80.91 613.79531.2 613.1 p-Toluenesulphonate 172.20 705.08 170.9 531.1 703.12-Naphtalenesulfonate 208.24 741.12 206.9 531.1 739.3 Hemisulfate 98.071163.8 531.1 (1:2) 631.0 630.85 (1:1) Methanesulphonate 96.11 628.99531.1 627.1 Nitrate 63.01 595.89 531.0 594.0 Hydrochloride 36.46 569.34531.0 569.0

All salts formed in this Example were amorphous.

Example 18-B

Further amorphous salts of Compound B were made using analogoustechniques to those described in Example 18-A above for the followingacids:

-   1,2-Ethanedisulfonic (0.5 salt)-   1S-Camphorsulfonic-   (+/−)-Camphorsulfonic-   p-Xylenesulfonic-   2-Mesitylenesulfonic-   Saccharin-   Maleic-   Phosphoric-   D-glutamic-   L-arginine-   L-lysine-   L-lysine * HCl

Example 18-C

Preparation of Amorphous Compound B, hemi-1,5-naphtalenedisulfonic acidsalt

Amorphous Compound B (110.9 mg) was dissolved in 2.5 mL 2-propanol and0.5 equivalent of 1,5-naphthalene-disulfonic acid tetrahydrate was added(dissolved in 1 mL 2-propanol). The sample was stirred overnight. Onlysmall particles (amorphous) or oil drops were observed by microscopy.The sample was evaporated to dryness.

Example 18-D

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

The crystallization experiment was carried out at ambient temperature.Amorphous Compound B (0.4 gram) was dissolved in ethanol (1.5 mL) and0.5 eq of 1,5-naphthalene-disulfonic acid tetrahydrate (1.35 gram, 10%in ethanol) was added. Heptane (0.7 mL) was then added until thesolution became slightly cloudy. After about 15 minutes the solutionbecame turbid. After about 30 minutes thin slurry was obtained andadditional heptane (1.3 mL) was added. The slurry was than leftovernight for ripening. To dilute the thick slurry, a mixture of ethanoland heptane (1.5 mL and 1.0 mL respectively) was added. After about 1hour the slurry was filtered and the crystals were washed with a mixtureof ethanol and heptane (1.5:1) and finally with pure heptane. Thecrystals were dried at ambient temperature in 1 day. The dry crystalsweighed 0.395 g.

Example 18-E

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

Amorphous Compound B (1.009 gr) was dissolved in 20 mL 2-propanol+20 mLethyl acetate. 351.7 mg 1,5-naphtalene-disulfonic acid tetrahydrate,dissolved in 20 mL 2-propanol, was added drop by drop. Precipitationoccurred in about 5 minutes. The slurry was stirred over night and thenfiltered.

Example 18-F

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

430.7 mg of the 1,5-naphtalene-disulfonic acid salt was dissolved in 30mL 1-propanol. The solution was heated to boiling in order to dissolvethe substance. The solution was left over night at ambient temperaturefor crystallization and then the crystals were filtered off.

Example 18-G

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

The mother liquid from Example 18-F was evaporated and the solid rest(61.2 mg) was dissolved in 6 mL acetonitrile/1-propanol, ratio 2:1. Thesolution was left overnight at ambient temperature to crystallize andthen the crystals were filtered off.

Example 18-H

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

The sample from Example 18-C was dissolved in about 2 mL methanol.Ethanol (about 3 mL) was added as anti-solvent at ambient temperatureand seeds were added. No crystallization occurred, so solvents wereevaporated (about half of the amount) and a new portion of ethanol(about 2 mL) and seeds were added. Crystalline particles were formedwhen stirred at ambient temperature during night.

Example 18-I

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

Amorphous Compound B (104.1 mg) was dissolved in 2-propanol and 1equivalent of 1,5-naphthalene-disulfonic acid tetrahydrate, dissolved in2-propanol, was added In total, the 2-propanol amount was about 2.5 mL.The solution was stirred at 44° C. for about 80 minutes and aprecipitate was formed. The particles were crystalline according topolarised light microscopy. The sample was filtered.

Example 18-J

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

Compound B, hemi-1,5-naphtalenedisulfonic acid salt (56.4 mg) wasdissolved in 1.5 mL methanol. Methyl ethyl ketone (3 mL) was added.Seeds were added to the solution and crystallization started. Thecrystals were filtered off, washed with methyl ethyl ketone and airdried.

Example 18-K

Preparation of Crystalline Compound B, hemi-1,5-naphtalenedisulfonicacid salt

Amorphous Compound B (161.0 mg) was dissolved in 3.5 mL 1-Butanol andthe solution was heated to 40° C. In another beaker 57.4 mg ofnaphthalene-disulfonic acid tetrahydrate was dissolved in 3 mL1-Butanol. A couple of drops of the acid solution were added to thesolution of compound B. Then seeds were added to the solution and after2 hours the rest of the acid solution was added (at 40° C.) slowly. Thenthe temperature was slowly decreased to room temperature and theexperiment was left under stirring overnight. The slurry was filtered,washed with 1-Butanol and dried under vacuum at 44° C. for 2 hours. Theyield was 83%.

Characterisation

Crystals of Compound B, hemi-1,5-naphtalenedisulfonic acid salt,obtained by way of Example 18-D above, was charaterised by NMR asfollows:

21.3 mg of the salt was dissolved in deuterated methanol, 0.7 ml wasinvestigated with NMR spectroscopy. A combination of 1D (¹H, ¹³C andselective NOE) and 2D (gCOSY, gHSQC and gHMBC) NMR experiments was used.

All data are in good agreement with the proposed structure, shown below.All carbons and the protons attached to carbons are assigned. Protonsattached to heteroatoms are exchanged for deuterium from the solvent andare not detected. Most resonances in the 1D ¹H and ¹³C NMR spectra arepresent as sets of two peaks. The reason for this is a slow rotationaround the C9-N10 bond, which results in two atropisomers thatsimultaneously exist in the solution. The 1D NOE experiment is anevidence for this. When a resonance of one atropisomer is irradiated,the saturation is transferred to the corresponding peak of the otheratropisomer. The resonances corresponding to the1,5-naphtalenedisulfonate counter ion do not show atropisomerism.

There are four fluorine atoms in the molecule. They give rise to splitresonances for some protons and carbons. Both the proton and the carbonresonance corresponding to position 1 are split due to the spincouplingwith the two fluorine nuclei in that position. The coupling constantsare ²J_(HF)=73 Hz and ¹J_(CF)=263 Hz. Further, the proton resonancecorresponding to H19 is a distorted doublet with ³J_(HF)=6.9 Hz due tothe spincoupling with the fluorine nuclei in position 18. Carbonresonances corresponding to C17, C18, C19 and C20 also exhibit couplingswith these fluorine nuclei. The C17 and C20 resonances are triplets with²J_(CF)=19 Hz and ³J_(CF)=11 Hz, respectively. The C18 resonance is adoublet of doublets with coupling constants ¹J_(CF)=251 Hz and ³J_(CF)=8Hz. The C19 resonance is a multiplet.

Comparing the magnitudes of integrals for resonances corresponding tothe 1,5-naphtalenedisulfonate counter ion and the mother compound givesthe stoichiometric relation of a single 1,5-naphtalenedisulfonatecounter ion crystallized with two molecules of the mother compound.

¹H and ¹³C NMR chemical shift assignment and proton-proton correlationsare shown in Table 11. TABLE 11 Atom ¹³C shift/ ¹H shift/ppm^(b) andThrough-bond No. Typ ppm^(a) multiplicity^(c) J_(HH)/Hz correlation to¹H^(d)  1 CHF₂ 117.5^(e) 6.91 (t) 73 (²J_(HF)) nd  1′ 117.5^(e) 6.87 (t)73 (²J_(HF)) nd  2 C 153.5 na na na  2′ 153.3 na na na  3 CH 120.0 7.14(t)^(n) nd 5, 7  3′ 119.6 7.11 (t)^(n) nd 5′, 7′  4 C 136.1 na na na  4′135.8 na na na  5 CH 125.0 7.31 (t)^(n) nd 3, 7  5′ 124.9 7.28 (t)^(n)nd 3′, 7′  6 C 144.4 na na na  6′ 145.3 na na na  7 CH 117.2 7.16(t)^(n) nd 3, 5  7′ 117.1 7.12 (t)^(n) nd 3′, 5′  8 CH  72.9 5.15 (s) nand  8′  73.6 5.07 (s) na nd  9 CO 173.0 na na na  9′ 173.5 na na na 11CH₂  51.5 a: 4.29 (m) b: 4.13 (m) nd 12, 13 11′  48.6 a: 4.01 (m) b:3.93 (m) nd 12′, 13′ 12 CH₂  21.7 a: 2.46 (m) b: 2.17 (m) nd 11, 13 12′ 22.8 a: 2.61 (m) b: 2.03 (m) nd 11′, 13′ 13 CH  62.8 4.70 (dd) 6.0 and9.4 12 13′  65.8 5.14 (dd) 5.6 and 9.1 12′ 14 CO 172.4 na na na 14′173.2 na na na 16 CH₂  32.3 4.51 (m) nd nd 16′  32.5 4.51 (m) nd nd 17 C121.0^(f) na na na 18 CF 162.8^(g) na na na 19 CH 112.7^(i) 7.35 (d) 6.9(³J_(HF)) nd 20 C 127.9^(k) na na na 21 C 160.0 na na na 21′ 159.9 na nana 24 CH₃  64.8 3.93 (s) na nd 24′  64.8 3.92 (s) na nd 25 C 142.4 na nana 26 CH 126.8 8.16 (d) 7.2 27, 28 27 CH 125.9 7.54 (dd) 8.6 and 7.2 26,28 28 CH 131.0 8.97 (d) 8.6 26, 27 29 C 131.1 na na na^(a)Relative to the solvent resonance at 49.0 ppm.^(b)Relative to the solvent resonance at 3.30 ppm.^(c)s = singlet, d = doublet, dd = doublet of doublets, t = triplet, m =multiplet.^(d)Obtained in the gCOSY experiment.^(e)The resonance is a triplet due to coupling with the two fluorinenuclei F1.¹J_(CF) = 263 Hz.^(f)The resonance is a triplet due to coupling to the two fluorinenuclei F18.²J_(CF) = 19 Hz.^(g)The resonance is a doublet of doublets due to coupling to the twofluorine nuclei F18. ¹J_(CF) = 251 Hz and³J_(CF) = 8 Hz.^(i)The resonance is a multiplet due to coupling to the two fluorinenuclei F18.^(k)The resonance is a triplet due to coupling to the two fluorinenuclei F18.³J_(CF) = 11 Hz.^(n)The ⁴J_(HH) coupling with the meta-protons is not fully resolved.na = not applicable,nd = not determined

Crystals of Compound B, hemi-1,5-naphtalenedisulfonic acid salt(obtained by way of Example 18-I above, were analyzed by XRPD and theresults are tabulated below (Table 12) and are shown in FIG. 5. TABLE 12Intensity d value (Å) (%) Intensity 18.3 99 vs 12.5 22 s 9.9 22 s 9.1 67vs 8.0 18 m 7.5 17 m 6.8 37 s 6.7 59 s 6.1 39 s 6.0 21 s 5.6 66 vs 5.598 vs 4.94 48 s 4.56 59 s 4.39 35 s 4.27 33 s 4.13 81 vs 4.02 87 vs 3.8688 vs 3.69 69 vs 3.63 100 vs 3.57 49 s 3.48 53 s 3.23 35 s 3.19 43 s3.16 38 s

DSC showed an endotherm with an extrapolated melting onset temperatureof ca 183° C. and TGA showed a 0.3% weight loss between 25-110° C.

EXAMPLE 19 Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe)benzensulfonic acid salt

N-methylmorpholine: NMM

0-(1-H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate:TBTU

To a stirred solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)OH (12.6 g, 50mmol) in ethyl acetate (126 ml) at 0° C. is added N-methylmorpholine(16.5 ml, 150 mmol), HAze-Pab(OMe).2HCl (16.8 g, 50 mmol; see Compound C(vi) description herein) and TBTU (16.7, 50 mmol). The reaction isallowed to warm to room temperature and is stirred overnight. Thereaction mixture is washed with water, 15% w/v potassium carbonatesolution, water, brine and water, dried and concentrated.

To the partially concentrated solution ethyl acetate (115 ml) is added asolution of benzene sulfonic acid (7.1 g, 45 mmol) in 2-propanol (38.4ml) at 40° C. The solution was seeded and stirred for 2 hours at 40° C.followed by stirring overnight at room temperature. When precipitationof the besylate salt is complete the product is filtered, washed anddried under vacuum at 40° C., to afford the sub title compound (22.6 g,69%).

EXAMPLE 20 Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe)

The coupling reaction of Example 19 may be repeated usingHAze-Pab(2,6-diF)(OMe), and the final product precipitated, for example,as the hemi-1,5-naphtalenedisulfonic acid salt.

To a stirred solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)OH (10.6 g, 42mmol) in ethyl acetate ( 66 ml) at 0° C. is added N-methylmorpholine(6.2 g, 61.2 mmol), HAze-Pab(2,6-diF) (OMe) (readily prepared from Cpd Bprep. (xi), 12.0 g, 38.2 mmol) and TBTU (15.3 g, 48 mmol). The reactionis allowed to warm to room temperature and is stirred overnight. Thereaction mixture is washed with water, 15% w/v potassium carbonatesolution (×2), water, brine and water, dried and partially concentrated.The solution is dried with anhydrous sodium sulfate (24 g), the dryingagent filtered off and the filtrate concentrated down to a foam (12.2 g,60%). Abbreviations Ac = acetyl APCI = atmospheric pressurechemicalionisation (in relation to MS) API = atmospheric pressureionisation (in relation to MS) aq. = aqueous Aze(&(S)-azetidine-2-carboxylate (unless otherwise specified) (S)-Aze) = Boc= tert-butyloxycarbonyl br = broad (in relation to NMR) CI = chemicalionisation (in relation to MS) d = day(s) d = doublet (in relation toNMR) DCC = dicyclohexyl carbodiimide dd = doublet of doublets (inrelation to NMR) DIBAL-H = di-isobutylaluminium hydride DIPEA =diisopropylethylamine DMAP = 4-(N,N-dimethyl amino) pyridine DMF =N,N-dimethylformamide DMSO = dimethylsulfoxide DSC = differentialscanning calorimetry DVT = deep vein thrombosis EDC =1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride eq. =equivalents ES = electrospray ESI = electrospray interface Et = ethylether = diethyl ether EtOAc = ethyl acetate EtOH = ethanol Et₂O =diethyl ether FT-IR = Fourier-transform infra-red spectroscopy gCOSY =gradient-selective correlated spectroscopy gHMBC = gradient-selectiveheteronuclear multiple bond correlation spectroscopy gHSQC =gradient-selective heteronuclear single quantum coherence HATU =O-(azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate HBTU = [N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium hexafluorophosphate] HCl = hydrochloric acid, hydrogenchloride gas or hydrochloride salt (depending on context) Hex = hexanesHOAc = acetic acid HPLC = high performance liquid chromatography LC =liquid chromatography m = multiplet (in relation to NMR) Me = methylMeOH = methanol min. = minute(s) MS = mass spectroscopy MTBE = methyltert-butyl ether NOE = nuclear Overhauser enhancement NMR = nuclearmagnetic resonance OAc = acetate Pab = para-amidinobenzylamino H-Pab =para-amidinobenzylamine Pd/C = palladium on carbon Ph = phenyl PyBOP =(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate q =quartet (in relation to NMR) QF = tetrabutylammonium fluoride rt/RT =room temperature s = singlet (in relation to NMR) t = triplet (inrelation to NMR) TBTU = [N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate] TEA = triethylamine Teoc =2-(trimethylsilyl)ethoxycarbonyl TEMPO =2,2,6,6-tetramethyl-1-piperidinyloxy free radical TFA = trifluoroaceticacid TGA = thermogravimetric analysis THF = tetrahydrofuran TLC = thinlayer chromatography UV = ultraviolet XRPD = X-ray powder diffraction

Prefixes n-, s-, i-, t- and tert- have their usual meanings: normal,secondary, iso, and tertiary.

Particular aspects of the invention are provided as follows:

When aspects refer to other aspects, this reference also includessub-aspects. For example, reference to aspect 14 includes reference toaspects 14 and 14A.

1. A pharmaceutically-acceptable acid addition salt of a compound offormula I,

wherein

-   R¹ represents C₁₋₂ alkyl substituted by one or more fluoro    substituents;-   R² represents C₁₋₂ alkyl; and-   n represents 0, 1 or 2.

2. A compound as described in aspect 1, wherein the acid is an organicacid.

3. A compound as described in aspect 2, wherein the acid is a sulfonicacid.

4. A compound as described in aspect 3, wherein the acid is1,2-ethanedisulfonic acid, a camphorsulfonic acid, ethanesulfonic acid,a propanesulfonic acid, a butanesulfonic acid, a pentanesulfonic acid, atoluenesulfonic acid, methanesulfonic acid, p-xylenesulfonic acid,2-mesitylenesulfonic acid, a naphthalenesulfonic acid, benzenesulfonicacid, a hydroxybenzenesulfonic acid, 2-hydroxyethanesulfonic acid or3-hydroxyethanesulfonic acid.

5. A compound as described in aspect 3, wherein the acid is a C₁₋₆alkanesulfonic acid or an optionally substituted arylsulfonic acid or anoptionally substituted aryldisulfonic acid.

6. A compound as described in aspect 4 or aspect 5, wherein the acid isethanesulfonic acid, n-propanesulfonic acid or benzenesulfonic acid.

6A. A compound as described in aspect 4 or aspect 5, wherein the acid isethanesulfonic acid, n-propanesulfonic acid, benzenesulfonic acid,1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid.

7. A compound as described in any one of aspects 1 to 6, wherein R¹represents —OCHF₂ or —OCH₂CH₂F.

8. A compound as described in any one of aspects 1 to 7, wherein R²represents methyl.

9. A compound as described in any one of aspects 1 to 8, wherein nrepresents 0 or 2.

10. A compound as described in aspect 9, wherein, when n represents 2,the two fluoro atoms are located at the two ortho-positions relative tothe point of attachment of the benzene ring to the —NH—CH₂— group.

11. A compound as described in any one of aspects 1 to 10, wherein thecompound of formula I isPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe).

12. A compound as desrcibed in any one of aspects 1 to 10, wherein thecompound of formula I isPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe).

13. A compound as described in any one of aspects 1 to 10, wherein thecompound of formula I isPh(3-Cl)(5-OCH₂CH₂F)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe).

14. A compound as described in any one of aspects 1 to 13 insubstantially crystalline form.

14A. A compound as described in any one of aspects 1 to 13 in partiallycrystalline form.

15. A compound as described in any one of aspects 1 to 9, 11 or 14,which is Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ethanesulfonicacid salt.

16. A compound as described in aspect 15, characterised by adifferential scanning calorimetry curve, at a heating rate of 10° C./minin a closed pan with a pinhole under flowing nitrogen, exhibiting anendotherm with an extrapolated onset temperature of about 131° C.;and/or an X-ray powder diffraction pattern characterised by peaks withd-values at 16.5, 12.2, 9.0, 7.6, 6.2, 6.0, 5.9, 5.5, 5.4, 5.1, 4.66,4.60, 4.31, 4.25, 4.19, 4.13, 4.00, 3.87, 3.83, 3.76, 3.72, 3.57, 3.51,3.47, 3.31, 3.26, 3.21, 3.03, 2.74, 2.56, 2.50, 2.46 and 2.21 Å, and/oressentially as defined in Table 3 and/or in FIG. 1.

16A. A compound as described in aspect 16, characterised by an X-raypowder diffraction pattern characterised by peaks with strong and verystrong intensity as defined in Table 3.

17. A compound as described in any one of aspects 1 to 9, 11 or 14,which is Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe),benzene-sulfonic acid salt.

18. A compound as described in aspect 17, characterised by adifferential scanning calorimetry curve, at a heating rate of 10° C./minin a closed pan with a pinhole under flowing nitrogen, exhibiting anendotherm with an extrapolated onset temperature of about 152° C.;and/or an X-ray powder diffraction pattern characterised by peaks withd-values at 14.2, 12.6, 10.2, 7.5, 6.4, 6.3, 6.1, 5.9, 5.7, 5.4, 5.3,5.1, 4.83, 4.73, 4.54, 4.50, 4.35, 4.30, 4.24, 4.17, 4.09, 4.08, 3.96,3.91, 3.77, 3.62, 3.52, 3.31, 3.19, 3.15, 3.09, 3.00, 2.79, 2.76, 2.72,2.59, 2.56, 2.54, 2.49 and 2.38 Å, and/or essentially as defined inTable 5 and/or in FIG. 2.

18A. A compound as described in aspect 18, characterised by an X-raypowder diffraction pattern characterised by peaks with strong and verystrong intensity as defined in Table 5.

19. A compound as described in any one of aspects 1 to 9, 11 or 14,which is Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe),n-propane-sulfonic acid salt.

20. A compound as described in aspect 19, characterised by adifferential scanning calorimetry curve, at a heating rate of 10° C./minin a closed pan with a pinhole under flowing nitrogen, exhibiting anendotherm with an extrapolated onset temperature of about 135° C.;and/or an X-ray powder diffraction pattern characterised by peaks withd-values at 12.4, 10.0, 7.5, 6.2, 5.8, 5.7, 5.4, 5.3, 4.78, 4.68, 4.51,4.49, 4.40, 4.32, 4.29, 4.25, 4.19, 4.14, 4.07, 4.04, 3.94, 3.88, 3.73,3.48, 3.28, 2.97, 2.54, 2.51 and 2.46 Å, and/or essentially as definedin Table 7 and/or in FIG. 3.

20A. A compound as described in aspect 20, characterised by an X-raypowder diffraction pattern characterised by peaks with strong and verystrong intensity as defined in Table 7.

20.B A compound as described in any one of aspects 1 to 10, 12, 14 or14A, wherein the compound of formula I isPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe),hemi-1,5-naphtalenedisulfonic acid salt.

20C. A compound as described in aspect 20B, characterised by an X-raypowder diffraction pattern characterised by peaks with strong and verystrong intensity as defined in Table 12.

21. A process for the preparation of a compound as described in any oneof aspects 1 to 20, which process comprises addition of an acid to acompound of formula I as defined in aspect 1.

22. A process for the preparation of a compound as described in aspect14, or any one of aspects 15 to 20 (as dependent on aspect 14), whichprocess comprises crystallising a compound as described in any one ofaspects 1 to 13.

23. A process for the preparation of a compound as described in aspect14, or any one of aspects 15 to 20 (as dependent on aspect 14), whichprocess comprises a process as described in aspect 21 followed by aprocess as described in aspect 22.

24. A process as described in aspect 22 or aspect 23, which comprisescrystallising the compound from a solvent.

25. A process as described in aspect 24, wherein the solvent is selectedfrom the group: lower alkyl acetates, lower alkyl alcohols, lowerdialkyl ketones, aliphatic hydrocarbons and aromatic hydrocarbons.

26. A process as described in aspect 24, which comprises dissolving acompound as defined in aspect 1 in amorphous form in a solvent selectedfrom the group lower alkyl alcohols, lower alkyl acetates, lower dialkylketones, and mixtures thereof, and subsequent crystallisation.

27. A process as described in aspect 26 which comprises either:

-   (a) dissolving the compound in a lower alkyl alcohol, and then    addition of a lower alkyl acetate or a lower dialkyl ketone; or-   (b) dissolving the compound in a mixture of a lower alkyl alcohol    and a lower alkyl acetate, or a mixture of a lower alkyl alcohol and    a lower dialkyl ketone.

28. A process as described in aspect 27 wherein the solvents areselected from the group: methyl iso-butyl ketone, iso-propanol, ethylacetate, iso-propyl acetate and mixtures thereof.

29. A process as described in aspect 24, which comprises a process asdescribed in aspect 21, followed by direct crystallisation of thecompound so formed from a solvent system that comprises a lower alkylacetate, a lower dialkyl ketone or a hydrocarbon.

30. A process as described in aspect 29 wherein the solvent system isselected from the group: iso-propanol, iso-propyl acetate, n-butylacetate, toluene, methyl iso-butyl ketone, ethyl acetate and mixturesthereof.

31. A process as described in aspect 24, which comprises pre-formingcompound of formula I in a lower alkyl alcohol, followed by addition ofa lower alkyl acetate, a lower dialkyl ketone or a hydrocarbon.

31A. A process as described in any of aspects 25 to 31, wherein the termlower alkyl denotes linear or branched (1-4C)alkyl.

32. A process as described in aspect 31 wherein the solvents areselected from the group: methanol, ethanol, iso-propanol, methyliso-butyl ketone, n-butyl acetate, toluene, iso-octane, n-heptane, ethylacetate and iso-propyl acetate.

33. A process for the preparation of a crystalline compound as definedin aspect 15 or aspect 16, which comprises slurrying pre-formed salt ineither methyl iso-butyl ketone or a mixture of iso-propanol and ethylacetate.

34. A process for the preparation of a crystalline compound as definedin aspect 15 or aspect 16, which comprises adding ethanesulfonic acid(optionally in the form of a solution in methyl iso-butyl ketone) to asolution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) in methyliso-butyl ketone.

35. A process for the preparation of a crystalline compound as definedin aspect 15 or aspect 16, which comprises adding ethanesulfonic acid toa solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) iniso-propanol, and then adding ethyl acetate as antisolvent.

36. A process for the preparation of a crystalline compound as definedin aspect 17 or aspect 18, which comprises slurrying pre-formed salt inethyl acetate, methyl iso-butyl ketone or iso-propyl acetate.

37. A process for the preparation of a crystalline compound as definedin aspect 17 or aspect 18, which comprises adding benzenesulfonic acidto a solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) inethyl acetate and then adding iso-propanol to facilitatecrystallisation.

38. A process for the preparation of a crystalline compound as definedin aspect 17 or aspect 18, which comprises adding benzenesulfonic acidto a solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) iniso-propanol and then adding ethyl acetate as antisolvent.

39. A process for the preparation of a crystalline compound as definedin aspect 19 or aspect 20, which comprises slurrying pre-formed salt ina mixture of iso-propanol and iso-propyl acetate, or in a mixture ofiso-propanol and ethyl acetate.

40. A process for the preparation of a crystalline compound as definedin aspect 19 or aspect 20, which comprises adding n-propanesulfonic acidto a solution of Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) iniso-propanol and then adding ethyl acetate, or iso-propyl acetate, asantisolvent.

41. A compound obtainable by a process according to any one of aspects21 to 40.

42. A compound as desrcibed in any one of aspects 1 to 20 or 41 for useas a medicament.

43. A pharmaceutical formulation including a compound as defined in anyone of aspects 1 to 20 or 41 in admixture with a pharmaceuticallyacceptable adjuvant, diluent or carrier.

44. A compound as defined in any one of aspects 1 to 20 or 41, or apharmaceutically acceptable derivative thereof, for use as apharmaceutical.

45. A compound as defined in any one of aspects 1 to 20 or 41, or apharmaceutically acceptable derivative thereof, for use in the treatmentof a condition where inhibition of thrombin is required.

46. A compound as defined in any one of aspects 1 to 20 or 41, or apharmaceutically acceptable derivative thereof, for use in the treatmentof a condition where anticoagulant therapy is indicated.

47. A compound as defined in any one of aspects 1 to 20 or 41, or apharmaceutically acceptable derivative thereof, for use in the treatmentof thrombosis.

48. A compound as defined in any one of aspects 1 to 20 or 41, or apharmaceutically acceptable derivative thereof, for use as ananticoagulant.

49. The use of a compound as defined in any one of aspects 1 to 20 or41, or a pharmaceutically acceptable derivative thereof, as an activeingredient for the manufacture of a medicament for the treatment of acondition where inhibition of thrombin is required.

50. The use of a compound as defined in any one of aspects 1 to 20 or41, or a pharmaceutically acceptable derivative thereof, as an activeingredient for the manufacture of a medicament for the treatment of acondition where anticoagulant therapy is indicated.

51. The use as described in aspect 49 or aspect 50, wherein thecondition is thrombosis.

52. The use as described in aspect 49 or aspect 50, wherein thecondition is hypercoagulability in blood and/or tissues.

53. The use of a compound as defined in any one of aspects 1 to 20 or41, or a pharmaceutically acceptable derivative thereof, as an activeingredient for the manufacture of an anticoagulant.

54. A method of treatment of a condition where inhibition of thrombin isrequired which method comprises administration of a therapeuticallyeffective amount of a compound as defined in any one of aspects 1 to 20or 41, or a pharmaceutically acceptable derivative thereof, to a personsuffering from, or susceptible to, such a condition.

55. A method of treatment of a condition where anticoagulant therapy isindicated which method comprises administration of a therapeuticallyeffective amount of a compound as defined in any one of aspects 1 to 20or 41, or a pharmaceutically acceptable derivative thereof, to a personsuffering from, or susceptible to, such a condition.

56. A method as described in aspect 54 or aspect 55, wherein thecondition is thrombosis.

57. A method as described in aspect 54 or aspect 55, wherein thecondition is hypercoagulability in blood and/or tissues.

1. A pharmaceutically acceptable acid addition salt of a compound offormula I,

wherein R¹ is C₁₋₂ alkyl substituted with one or more fluorosubstituents; R² is C₁₋₂ alkyl; and n is 0, 1, or
 2. 2. An acid additionsalt as claimed in claim 1, wherein the acid is a sulfonic acid.
 3. Anacid addition salt as claimed in claim 1, wherein the acid ismethanesulfonic acid, n-propanesulfonic acid, benzenesulfonic acid,1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid.
 4. An acidaddition salt as claimed in claim 1, wherein R¹ is —OCHF₂ or —OCH₂CH₂F.5. An acid addition salt as claimed in claim 1, wherein R² is methyl. 6.An acid addition salt as claimed in claim 1, wherein n is 0 or
 2. 7. Anacid addition salt as claimed in claim 1, wherein the compound offormula I is Ph(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) orPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe).
 8. An acidaddition salt as claimed in claim 1 in substantially crystalline form.9. An acid addition salt as claimed in claim 1 in partially crystallineform.
 10. An acid addition salt as claimed in claim 8, wherein n is 0.11. An acid addition salt as claimed in claim 9, wherein n is
 2. 12. Anacid addition salt as claimed in claim 10, which isPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(OMe) benzene-sulfonic acidsalt, characterised by an X-ray powder diffraction pattern characterisedby peaks with d-values at 5.9, 4.73, 4.09, and 4.08 Å.
 13. An acidaddition salt as claimed in claim 11, which isPh(3-Cl)(5-OCHF₂)—(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe)hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-raypowder diffraction pattern characterised by peaks with d-values at 18.3,9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63 Å.
 14. A process for thepreparation of an acid addition salt as claimed in any one of claims 1to 3, which process comprises addition of an acid to a compound offormula I.
 15. A process as claimed in claim 14, which process furthercomprises crystallising the acid addition salt.
 16. A pharmaceuticalformulation comprising an acid addition salt of any one of claims 1 to3, in admixture with a pharmaceutically acceptable adjuvant, diluent, orcarrier. 17-18. (canceled)
 19. A method for treating a condition whereinhibition of thrombin is required, comprising administering atherapeutically effective amount of an acid addition salt of any one ofclaims 1 to 3, to a person suffering from, or susceptible to, such acondition.